Novel human transporter proteins and polynucleotides encoding the same

ABSTRACT

Novel human polynucleotide and polypeptide sequences are disclosed that can be used in therapeutic, dignostic, and pharmacogenomic applicants.

[0001] The present application claims the benefit of U.S. Provisional Application No. 60/187,120 and 60/204,725, which were filed on Mar. 6, 2000 and May 16, 2000, respectively, and which are herein incorporated by reference in their entirety.

INTRODUCTION

[0002] The present invention relates to the discovery, identification, and characterization of novel human polynucleotides encoding proteins that share sequence similarity with mammalian transporter proteins. The invention encompasses the described polynucleotides, host cell expression systems, the encoded proteins, fusion proteins, polypeptides and peptides, antibodies to the encoded proteins and peptides, and genetically engineered animals that either lack or over express the disclosed polynucleotides, antagonists and agonists of the proteins, and other compounds that modulate the expression or activity of the proteins encoded by the disclosed polynucleotides that can be used for diagnosis, drug screening, clinical trial monitoring, and treatment of diseases and disorders.

BACKGROUND OF THE INVENTION

[0003] Transporter proteins are-integral membrane proteins that mediate or facilitate the passage of materials across the lipid bilayer. Given that the transport of materials across the membrane can play an important physiological role, transporter proteins are good drug targets. Additionally, one of the mechanisms of drug resistance involves diseased cells using cellular transporter systems to export chemotherapeutic agents from the cell. Such mechanisms are particularly relevant to cells manifesting resistance to a multiplicity of drugs.

SUMMARY OF THE INVENTION

[0004] The present invention relates to the discovery, identification, and characterization of nucleotides that encode novel human proteins, and the corresponding amino acid sequences of these proteins. The novel human proteins (NHPs) described for the first time herein share structural similarity with mammalian sugar and sodium-dependent inorganic phosphate transporters, and NBMPR-sensitive nucleoside transporters.

[0005] The novel human nucleic acid sequences described herein, encode alternative proteins/open reading frames (ORFs) of 436, 392, 398, 284, 290, 430, 436, 392, 398, 284, 290, 430, 418, 355, 310, 247, 456 and 393 amino acids in length (sugar and inorganic phosphate transporters, SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34 and 36 respectively) and 475 amino acids in length (nucleoside transporter, SEQ ID NO:38).

[0006] The invention also encompasses agonists and antagonists of the described NHPs, including small molecules, large molecules, mutant NHPs, or portions thereof, that compete with native NHP, peptides, and antibodies, as well as nucleotide sequences that can be used to inhibit the expression of the described NHPs (e.g., antisense and ribozyme molecules, and gene or regulatory sequence replacement constructs) or to enhance the expression of the described NHP polynucleotides (e.g., expression constructs that place the described polynucleotide under the control of a strong promoter system), and transgenic animals that express a NHP transgene, or “knock-outs” (which can be conditional) that do not express a functional NHP. Knock-out mice can be produced in several ways, one of which involves the use of mouse embryonic stem cells (“ES cells”) lines that contain gene trap mutations in a murine homolog of at least one of the described NHPS. When the unique NHP sequences described in SEQ ID NOS:1-40 are “knocked-out” they provide a method of identifying phenotypic expression of the particular gene as well as a method of assigning function to previously unknown genes. Additionally, the unique NHP sequences described in SEQ ID NOS:1-40 are useful for the identification of coding sequence and the mapping a unique gene to a particular chromosome.

[0007] Further, the present invention also relates to processes for identifying compounds that modulate, i.e., act as agonists or antagonists, of NHP expression and/or NHP activity that utilize purified preparations of the described NHPs and/or NHP product, or cells expressing the same. Such compounds can be used as therapeutic agents for the treatment of any of a wide variety of symptoms associated with biological disorders or imbalances.

DESCRIPTION OF THE SEQUENCE LISTING AND FIGURES

[0008] The Sequence Listing provides the sequences of the described NHP ORFs that encode the described NHP amino acid sequences. SEQ ID NO:39 and 40 describe nucleotides encoding a NHP ORF with regions of flanking sequence.

DETAILED DESCRIPTION OF THE INVENTION

[0009] The NHPs described for the first time herein are novel proteins that may be expressed in, inter alia, human cell lines, fetal brain, brain, pituitary, cerebellum, thymus, spleen, lymph node, bone marrow, lung, kidney, fetal liver, liver, prostate, testis, thyroid, adrenal gland, pancreas, salivary gland, stomach, small intestine, skeletal muscle, uterus, placenta, mammary gland, adipose, skin, esophagus, bladder, cervix, rectum, pericardium, hypothalamus, ovary, fetal kidney, fetal lung, and gene trapped human cells. More particularly, the NHPs that are similar to sugar transporters are predominantly found in bone marrow, lymph node, trachea, and lung cDNA while expression of the NHP transporter that is similar to nucleoside transporters can be broadly detected in the tissues described above.

[0010] The present invention encompasses the nucleotides presented in the Sequence Listing, host cells expressing such nucleotides, the expression products of such nucleotides, and: (a) nucleotides that encode mammalian homologs of the described polynucleotides, including the specifically described NHPS, and the NHP products; (b) nucleotides that encode one or more portions of the NHPs that correspond to functional domains, and the polypeptide products specified by such nucleotide sequences, including but not limited to the novel regions of any active domain(s); (c) isolated nucleotides that encode mutant versions, engineered or naturally occurring, of the described NHPs in which all or a part of at least one domain is deleted or altered, and the polypeptide products specified by such nucleotide sequences, including but not limited to soluble proteins and peptides in which all or a portion of the signal (or hydrophobic transmembrane) sequence is deleted; (d) nucleotides that encode chimeric fusion proteins containing all or a portion of a coding region of an NHP, or one of its domains ( e.g., a receptor or ligand binding domain, accessory protein/self-association domain, etc.) fused to another peptide or polypeptide; or (e) therapeutic or diagnostic derivatives of the described polynucleotides such as oligonucleotides, antisense polynucleotides, ribozymes, dsRNA, or gene therapy constructs comprising a sequence first disclosed in the Sequence Listing. As discussed above, the present invention includes: (a) the human DNA sequences presented in the Sequence Listing (and vectors comprising the same) and additionally contemplates any nucleotide sequence encoding a contiguous NHP open reading frame (ORF) that hybridizes to a complement of a DNA sequence presented in the Sequence Listing under highly stringent conditions, e.g., hybridization to filter-bound DNA in 0.5 M NaHPO₄, 7% sodium dodecyl sulfate (SDS), 1 mM EDTA at 65° C., and washing in 0.1×SSC/0.1% SDS at 68° C. (Ausubel F.M. et al., eds., 1989, Current Protocols in Molecular Biology, Vol. I, Green Publishing Associates, Inc., and John Wiley & sons, Inc., New York, at p. 2.10.3) and encodes a functionally equivalent gene product. Additionally contemplated are any nucleotide sequences that hybridize to the complement of a DNA sequence that encodes and expresses an amino acid sequence presented in the Sequence Listing under moderately stringent conditions, e.g., washing in 0.2×SSC/0.1% SDS at 42° C. (Ausubel et al., 1989, supra), yet still encodes a functionally equivalent NHP product. Functional equivalents of a NHP include naturally occurring NHPs present in other species and mutant NHPs whether naturally occurring or engineered (by site directed mutagenesis, gene shuffling, directed evolution as described in, for example, U.S. Patent No. 5,837,458). The invention also includes degenerate nucleic acid variants of the disclosed NHP polynucleotide sequences.

[0011] Additionally contemplated are polynucleotides encoding NHP ORFs, or their functional equivalents, encoded by polynucleotide sequences that are about 99, 95, 90, or about 85 percent similar or identical to corresponding regions of the nucleotide sequences of the Sequence Listing (as measured by BLAST sequence comparison analysis using, for example, the GCG sequence analysis package using standard default settings).

[0012] The invention also includes nucleic acid molecules, preferably DNA molecules, that hybridize to, and are therefore the complements of, the described NHP nucleotide sequences. Such hybridization conditions may be highly stringent or less highly stringent, as described above. In instances where the nucleic acid molecules are deoxyoligonucleotides (“DNA oligos”), such molecules are generally about 16 to about 100 bases long, or about 20 to about 80, or about 34 to about 45 bases long, or any variation or combination of sizes represented therein that incorporate a contiguous region of sequence first disclosed in the Sequence Listing. Such oligonucleotides can be used in conjunction with the polymerase chain reaction (PCR) to screen libraries, isolate clones, and prepare cloning and sequencing templates, etc.

[0013] Alternatively, such NHP oligonucleotides can be used as hybridization probes for screening libraries, and assessing gene expression patterns (particularly using a micro array or high-throughput “chip” format). Additionally, a series of the described NHP oligonucleotide sequences, or the complements thereof, can be used to represent all or a portion of the described NHP sequences. An oligonucleotide or polynucleotide sequence first disclosed in at least a portion of one or more of the sequences of SEQ ID NOS: 1-40 can be used as a hybridization probe in conjunction with a solid support matrix/substrate (resins, beads, membranes, plastics, polymers, metal or metallized substrates, crystalline or polycrystalline substrates, etc.). Of particular note are spatially addressable arrays (i.e., gene chips, microtiter plates, etc.) of oligonucleotides and polynucleotides, or corresponding oligopeptides and polypeptides, wherein at least one of the biopolymers present on the spatially addressable array comprises an oligonucleotide or polynucleotide sequence first disclosed in at least one of the sequences of SEQ ID NOS: 1-40, or an amino acid sequence encoded thereby. Methods for attaching biopolymers to, or synthesizing biopolymers on, solid support matrices, and conducting binding studies thereon are disclosed in, inter alia, U.S. Patent Nos. 5,700,637, 5,556,752, 5,744,305, 4,631,211, 5,445,934, 5,252,743, 4,713,326, 5,424,186, and 4,689,405 the disclosures of which are herein incorporated by reference in their entirety.

[0014] Addressable arrays comprising sequences first disclosed in SEQ ID NOS:1-40 can be used to identify and characterize the temporal and tissue specific expression of a gene. These addressable arrays incorporate oligonucleotide sequences of sufficient length to confer the required specificity, yet be within the limitations of the production technology. The length of these probes is within a range of between about 8 to about 2000 nucleotides. Preferably the probes consist of 60 nucleotides and more preferably 25 nucleotides from the sequences first disclosed in SEQ ID NOS:1-40.

[0015] For example, a series of the described oligonucleotide sequences, or the complements thereof, can be used in chip format to represent all or a portion of the described sequences. The oligonucleotides, typically between about 16 to about 40 (or any whole number within the stated range) nucleotides in length can partially overlap each other and/or the sequence may be represented using oligonucleotides that do not overlap. Accordingly, the described polynucleotide sequences shall typically comprise at least about two or three distinct oligonucleotide sequences of at least about 8 nucleotides in length that are each first disclosed in the described Sequence Listing. Such oligonucleotide sequences can begin at any nucleotide present within a sequence in the Sequence Listing and proceed in either a sense (5′-to-3′) orientation vis-a-vis the described sequence or in an antisense orientation.

[0016] Microarray-based analysis allows the discovery of broad patterns of genetic activity, providing new understanding of gene functions and generating novel and unexpected insight into transcriptional processes and biological mechanisms. The use of addressable arrays comprising sequences first disclosed in SEQ ID NOS:1-40 provides detailed information about transcriptional changes involved in a specific pathway, potentially leading to the identification of novel components or gene functions that manifest themselves as novel phenotypes.

[0017] Probes consisting of sequences first disclosed in SEQ ID NOS:1-40 can also be used in the identification, selection and validation of novel molecular targets for drug discovery. The use of these unique sequences permits the direct confirmation of drug targets and recognition of drug dependent changes in gene expression that are modulated through pathways distinct from the drugs intended target. These unique sequences therefore also have utility in defining and monitoring both drug action and toxicity.

[0018] As an example of utility, the sequences first disclosed in SEQ ID NOS:1-40 can be utilized in microarrays or other assay formats, to screen collections of genetic material from patients who have a particular medical condition. These investigations can also be carried out using the sequences first disclosed in SEQ ID NOS:1-40 in silico and by comparing previously collected genetic databases and the disclosed sequences using computer software known to those in the art.

[0019] Thus the sequences first disclosed in SEQ ID NOS:1-40 can be used to identify mutations associated with a particular disease and also as a diagnostic or prognostic assay.

[0020] Although the presently described sequences have been specifically described using nucleotide sequence, it should be appreciated that each of the sequences can uniquely be described using any of a wide variety of additional structural attributes, or combinations thereof. For example, a given sequence can be described by the net composition of the nucleotides present within a given region of the sequence in conjunction with the presence of one or more specific oligonucleotide sequence(s) first disclosed in the SEQ ID NOS: 1-40. Alternatively, a restriction map specifying the relative positions of restriction endonuclease digestion sites, or various palindromic or other specific oligonucleotide sequences can be used to structurally describe a given sequence. Such restriction maps, which are typically generated by widely available computer programs (e.g., the University of Wisconsin GCG sequence analysis package, SEQUENCHER 3.0, Gene Codes Corp., Ann Arbor, Mich., etc.), can optionally be used in conjunction with one or more discrete nucleotide sequence(s) present in the sequence that can be described by the relative position of the sequence relatve to one or more additional sequence(s) or one or more restriction sites present in the disclosed sequence.

[0021] For oligonucleotide probes, highly stringent conditions may refer, e.g., to washing in 6×SSC/0.05% sodium pyrophosphate at 37° C. (for 14-base oligos), 48° C. (for 17-base oligos), 55° C. (for 20-base oligos), and 60° C. (for 23-base oligos). These nucleic acid molecules may encode or act as NHP gene antisense molecules, useful, for example, in NHP gene regulation (for and/or as antisense primers in amplification reactions of NHP gene nucleic acid sequences). With respect to NHP gene regulation, such techniques can be used to regulate biological functions. Further, such sequences may be used as part of ribozyme and/or triple helix sequences that are also useful for NHP gene regulation.

[0022] Inhibitory antisense or double stranded oligonucleotides can additionally comprise at least one modified base moiety which is selected from the group including but not limited to 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xantine, 4-acetylcytosine, 5-(carboxyhydroxylmethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5′-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (V), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2, 6-diaminopurine.

[0023] The antisense oligonucleotide can also comprise at least one modified sugar moiety selected from the group including but not limited to arabinose, 2-fluoroarabinose, xylulose, and hexose.

[0024] In yet another embodiment, the antisense oligonucleotide will comprise at least one modified phosphate backbone selected from the group consisting of a phosphorothioate, a phosphorodithioate, a phosphoramidothioate, a phosphoramidate, a phosphordiamidate, a methylphosphonate, an alkyl phosphotriester, and a formacetal or analog thereof.

[0025] In yet another embodiment, the antisense oligonucleotide is an α-anomeric oligonucleotide. An a-anomeric oligonucleotide forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual β-units, the strands run parallel to each other (Gautier et al., 1987, Nucl. Acids Res. 15:6625-6641). The oligonucleotide is a 2′-0-methylribonucleotide (Inoue et al., 1987, Nucl. Acids Res. 15:6131-6148), or a chimeric RNA-DNA analogue (Inoue et al., 1987, FEBS Lett. 215:327-330). Alternatively, double stranded RNA can be used to disrupt the expression and function of a targeted NHP.

[0026] Oligonucleotides of the invention can be synthesized by standard methods known in the art, e.g. by use of an automated DNA synthesizer (such as are commercially available from Biosearch, Applied Biosystems, etc.). As examples, phosphorothioate oligonucleotides can be synthesized by the method of Stein et al. (1988, Nucl. Acids Res. 16:3209), and methylphosphonate oligonucleotides can be prepared by use of controlled pore glass polymer supports (Sarin et al., 1988, Proc. Natl. Acad. Sci. U.S.A. 85:7448-7451), etc.

[0027] Low stringency conditions are well known to those of skill in the art, and will vary predictably depending on the specific organisms from which the library and the labeled sequences are derived. For guidance regarding such conditions see, for example, Sambrook et al., 1989, Molecular Cloning, A Laboratory Manual (and periodic updates thereof), Cold Springs Harbor Press, N.Y.; and Ausubel et al., 1989, Current Protocols in Molecular Biology, Green Publishing Associates and Wiley Interscience, N.Y.

[0028] Alternatively, suitably labeled NHP nucleotide probes can be used to screen a human genomic library using appropriately stringent conditions or by PCR. The identification and characterization of human genomic clones is helpful for identifying polymorphisms (including, but not limited to, nucleotide repeats, microsatellite alleles, single nucleotide polymorphisms, or coding single nucleotide polymorphisms), determining the genomic structure of a given locus/allele, and designing diagnostic tests. For example, sequences derived from regions adjacent to the intron/exon boundaries of the human gene can be used to design primers for use in amplification assays to detect mutations within the exons, introns, splice sites (e.g., splice acceptor and/or donor sites), etc., that can be used in diagnostics and pharmacogenomics.

[0029] Further, a NHP gene homolog can be isolated from nucleic acid from an organism of interest by performing PCR using two degenerate or “wobble” oligonucleotide primer pools designed on the basis of amino acid sequences within the NHP products disclosed herein. The template for the reaction may be total RNA, mRNA, and/or cDNA obtained by reverse transcription of mRNA prepared from human or non-human cell lines or tissue known or suspected to express an allele of a NHP gene.

[0030] The PCR product can be subcloned and sequenced to ensure that the amplified sequences represent the sequence of the desired NHP gene. The PCR fragment can then be used to isolate a full length cDNA clone by a variety of methods. For example, the amplified fragment can be labeled and used to screen a cDNA library, such as a bacteriophage cDNA library. Alternatively, the labeled fragment can be used to isolate genomic clones via the screening of a genomic library.

[0031] PCR technology can also be used to isolate full length cDNA sequences. For example, RNA can be isolated, following standard procedures, from an appropriate cellular or tissue source (i.e., one known, or suspected, to express a NHP gene). A reverse transcription (RT) reaction can be performed on the RNA using an oligonucleotide primer specific for the most 5′ end of the amplified fragment for the priming of first strand synthesis. The resulting RNA/DNA hybrid may then be “tailed” using a standard terminal transferase reaction, the hybrid may be digested with RNase H, and second strand synthesis may then be primed with a complementary primer. Thus, cDNA sequences upstream of the amplified fragment can be isolated. For a review of cloning strategies that can be used, see e.g., Sambrook et al., 1989, supra.

[0032] A cDNA encoding a mutant NHP gene can be isolated, for example, by using PCR. In this case, the first cDNA strand may be synthesized by hybridizing an oligo-dT oligonucleotide to mRNA isolated from tissue known or suspected to be expressed in an individual putatively carrying a mutant NHP allele, and by extending the new strand with reverse transcriptase. The second strand of the cDNA is then synthesized using an oligonucleotide that hybridizes specifically to the 5′ end of the normal gene. Using these two primers, the product is then amplified via PCR, optionally cloned into a suitable vector, and subjected to DNA sequence analysis through methods well known to those of skill in the art. By comparing the DNA sequence of the mutant NHP allele to that of a corresponding normal NHP allele, the mutation(s) responsible for the loss or alteration of function of the mutant NHP gene product can be ascertained.

[0033] Alternatively, a genomic library can be constructed using DNA obtained from an individual suspected of or known to carry a mutant NHP allele (e.g., a person manifesting a NHP-associated phenotype such as, for example, obesity, high blood pressure, connective tissue disorders, infertility, etc.), or a cDNA library can be constructed using RNA from a tissue known, or suspected, to express a mutant NHP allele. A normal NHP gene, or any suitable fragment thereof, can then be labeled and used as a probe to identify the corresponding mutant NHP allele in such libraries. Clones containing mutant NHP gene sequences can then be purified and subjected to sequence analysis according to methods well known to those skilled in the art.

[0034] Additionally, an expression library can be constructed utilizing cDNA synthesized from, for example, RNA isolated from a tissue known, or suspected, to express a mutant NHP allele in an individual suspected of or known to carry such a mutant allele. In this manner, gene products made by the putatively mutant tissue can be expressed and screened using standard antibody screening techniques in conjunction with antibodies raised against a normal NHP product, as described below. (For screening techniques, see, for example, Harlow, E. and Lane, eds., 1988, “Antibodies: A Laboratory Manual”, Cold Spring Harbor Press, Cold Spring Harbor, N.Y.).

[0035] Additionally, screening can be accomplished by screening with labeled NHP fusion proteins, such as, for example, alkaline phosphatase-NHP or NHP-alkaline phosphatase fusion proteins. In cases where a NHP mutation results in an expressed gene product with altered function ( e.g., as a result of a missense or a frameshift mutation), polyclonal antibodies to a NHP are likely to cross-react with a corresponding mutant NHP gene product. Library clones detected via their reaction with such labeled antibodies can be purified and subjected to sequence analysis according to methods well known in the art.

[0036] The invention also encompasses (a) DNA vectors that contain any of the foregoing NHP coding sequences and/or their complements (i.e., antisense); (b) DNA expression vectors that contain any of the foregoing NHP coding sequences operatively associated with a regulatory element that directs the expression of the coding sequences (for example, baculo virus as described in U.S. Pat. No. 5,869,336 herein incorporated by reference); (c) genetically engineered host cells that contain any of the foregoing NHP coding sequences operatively associated with a regulatory element that directs the expression of the coding sequences in the host cell; and (d) genetically engineered host cells that express an endogenous NHP gene under the control of an exogenously introduced regulatory element (i.e., gene activation). As used herein, regulatory elements include, but are not limited to, inducible and non-inducible promoters, enhancers, operators and other elements known to those skilled in the art that drive and regulate expression. Such regulatory elements include but are not limited to the cytomegalovirus (hCMV) immediate early gene, regulatable, viral elements (particularly retroviral LTR promoters), the early or late promoters of SV40 adenovirus, the lac system, the trp system, the TAC system, the TRC system, the major operator and promoter regions of phage lambda, the control regions of fd coat protein, the promoter for 3-phosphoglycerate kinase (PGK), the promoters of acid phosphatase, and the promoters of the yeast α-mating factors.

[0037] The present invention also encompasses antibodies and anti-idiotypic antibodies (including Fab fragments), antagonists and agonists of the NHP, as well as compounds or nucleotide constructs that inhibit expression of a NHP gene (transcription factor inhibitors, antisense and ribozyme molecules, or gene or regulatory sequence replacement constructs), or promote the expression of a NHP (e.g., expression constructs in which NHP coding sequences are operatively associated with expression control elements such as promoters, promoter/enhancers, etc.).

[0038] The NHPs or NHP peptides, NHP fusion proteins, NHP nucleotide sequences, antibodies, antagonists and agonists can be useful for the detection of mutant NHPs or inappropriately expressed NHPs for the diagnosis of disease. The NHP proteins or peptides, NHP fusion proteins, MHP nucleotide sequences, host cell expression systems, antibodies, antagonists, agonists and genetically engineered cells and animals can be used for screening for drugs (or high throughput screening of combinatorial libraries) effective in the treatment of the symptomatic or phenotypic manifestations of perturbing the normal function of NHP in the body. The use of engineered host cells and/or animals may offer an advantage in that such systems allow not only for the identification of compounds that bind to the endogenous receptor for an NHP, but can also identify compounds that trigger NHP-mediated activities or pathways.

[0039] Finally, the NHP products can be used as therapeutics. For example, soluble derivatives such as NHP peptides/domains corresponding to NHPs, NHP fusion protein products (especially NHP-Ig fusion proteins, i.e., fusions of a NHP, or a domain of a NHP, to an IgFc), NHP antibodies and anti-idiotypic antibodies (including Fab fragments), antagonists or agonists (including compounds that modulate or act on downstream targets in a NHP-mediated pathway) can be used to directly treat diseases or disorders. For instance, the administration of an effective amount of soluble NHP, or a NHP-IgFc fusion protein or an anti-idiotypic antibody (or its Fab) that mimics the NHP could activate or effectively antagonize the endogenous NHP receptor. Nucleotide constructs encoding such NHP products can be used to genetically engineer host cells to express such products in vivo; these genetically engineered cells function as “bioreactors” in the body delivering a continuous supply of a NHP, a NHP peptide, or a NHP fusion protein to the body. Nucleotide constructs encoding functional NHPS, mutant NHPs, as well as antisense and ribozyme molecules can also be used in “gene therapy” approaches for the modulation of NHP expression. Thus, the invention also encompasses pharmaceutical formulations and methods for treating biological disorders.

[0040] Various aspects of the invention are described in greater detail in the subsections below.

THE NHP SEQUENCES

[0041] The cDNA sequences and the corresponding deduced amino acid sequences of the described NHPs are presented in the Sequence Listing. The NHP nucleotides were obtained from clustered human gene trapped sequences, genomic sequence, ESTs, and cDNAs from human testis, lymph node, and bone marrow cDNA libraries (Edge Biosystems, Gaithersburg, MD).

[0042] SEQ ID NOS: 1-36 describe sequences that are similar to eucaryotic phosphate or sugar transporters.

[0043] SEQ ID NOS: 37-38 describe sequences that are similar to, inter alia, nucleoside transporters which may be nucleolar.

[0044] SEQ ID NOS: 39-40 describe a NHP ORF as well as flanking regions.

[0045] Transporters and transporter related multidrug resistance (MDR) sequences, as well as uses and applications that are germane to the described NHPs, are described in U.S. Patents Nos. 5,198,344 and 5,866,699 which are herein incorporated by reference in their entirety.

NHPS AND NHP POLYPEPTIDES

[0046] NHPs, polypeptides, peptide fragments, mutated, truncated, or deleted forms of the NHPs, and/or NHP fusion proteins can be prepared for a variety of uses. These uses include but are not limited to the generation of antibodies, as reagents in diagnostic assays, the identification of other cellular gene products related to a NHP, as reagents in assays for screening for compounds that can be as pharmaceutical reagents useful in the therapeutic treatment of mental, biological, or medical disorders and diseases. Given the similarity information and expression data, the described NHPs can be targeted (by drugs, oligos, antibodies, etc,) in order to treat disease, or to therapeutically augment the efficacy of, for example, chemotherapeutic agents used in the treatment of breast or prostate cancer.

[0047] The Sequence Listing discloses the amino acid sequences encoded by the described NHP polynucleotides. The NHPs typically display have initiator methionines in DNA sequence contexts consistent with a translation initiation site.

[0048] The NHP amino acid sequences of the invention include the amino acid sequence presented in the Sequence Listing as well as analogues and derivatives thereof. Further, corresponding NHP homologues from other species are encompassed by the invention. In fact, any NHP protein encoded by the NHP nucleotide sequences described above are within the scope of the invention, as are any novel polynucleotide sequences encoding all or any novel portion of an amino acid sequence presented in the Sequence Listing. The degenerate nature of the genetic code is well known, and, accordingly, each amino acid presented in the Sequence Listing, is generically representative of the well known nucleic acid “triplet” codon, or in many cases codons, that can encode the amino acid. As such, as contemplated herein, the amino acid sequences presented in the Sequence Listing, when taken together with the genetic code (see, for example, Table 4-1 at page 109 of “Molecular Cell Biology”, 1986, J. Darnell et al. eds., Scientific American Books, New York, N.Y., herein incorporated by reference) are generically representative of all the various permutations and combinations of nucleic acid sequences that can encode such amino acid sequences.

[0049] The invention also encompasses proteins that are functionally equivalent to the NHPs encoded by the presently described nucleotide sequences as judged by any of a number of criteria, including, but not limited to, the ability to bind and cleave a substrate of a NHP, or the ability to effect an identical or complementary downstream pathway, or a change in cellular metabolism (e.g., proteolytic activity, ion flux, tyrosine phosphorylation, etc.). Such functionally equivalent NHP proteins include, but are not limited to, additions or substitutions of amino acid residues within the amino acid sequence encoded by the NHP nucleotide sequences described above, but which result in a silent change, thus producing a functionally equivalent gene product. Amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues involved. For example, nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, and methionine; polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine; positively charged (basic) amino acids include arginine, lysine, and histidine; and negatively charged (acidic) amino acids include aspartic acid and glutamic acid.

[0050] A variety of host-expression vector systems can be used to express the NHP nucleotide sequences of the invention. Where, as in the present instance, the NHP peptide or polypeptide is thought to be membrane protein, the hydrophobic regions of the protein can be excised and the resulting soluble peptide or polypeptide can be recovered from the culture media. Such expression systems also encompass engineered host cells that express a NHP, or functional equivalent, in situ. Purification or enrichment of a NHP from such expression systems can be accomplished using appropriate detergents and lipid micelles and methods well known to those skilled in the art. However, such engineered host cells themselves may be used in situations where it is important not only to retain the structural and functional characteristics of the NHP, but to assess biological activity, e.g., in drug screening assays.

[0051] The expression systems that may be used for purposes of the invention include but are not limited to microorganisms such as bacteria (e.g., E. coli, B. subtilis) transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing NHP nucleotide sequences; yeast (e.g., Saccharomyces, Pichia) transformed with recombinant yeast expression vectors containing NHP nucleotide sequences; insect cell systems infected with recombinant virus expression vectors (e.g., baculovirus) containing NHP sequences; plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing NHP nucleotide sequences; or mammalian cell systems (e.g., COS, CHO, BHK, 293, 3T3) harboring recombinant expression constructs containing promoters derived from the genome of mammalian cells (e.g., metallothionein promoter) or from mammalian viruses (e.g., the adenovirus late promoter; the vaccinia virus 7.5K promoter).

[0052] In bacterial systems, a number of expression vectors may be advantageously selected depending upon the use intended for the NHP product being expressed. For example, when a large quantity of such a protein is to be produced for the generation of pharmaceutical compositions of or containing NHP, or for raising antibodies to a NHP, vectors that direct the expression of high levels of fusion protein products that are readily purified may be desirable. Such vectors include, but are not limited, to the E. coli expression vector pUR278 (Ruther et al., 1983, EMBO J. 2:1791), in which a NHP coding sequence may be ligated individually into the vector in frame with the lacZ coding region so that a fusion protein is produced; pIN vectors (Inouye & Inouye, 1985, Nucleic Acids Res. 13:3101-3109; Van Heeke & Schuster, 1989, J. Biol. Chem. 264:5503-5509); and the like. pGEX vectors (Pharmacia or American Type Culture Collection) can also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption to glutathione-agarose beads followed by elution in the presence of free glutathione. The PGEX vectors are designed to include thrombin or factor Xa protease cleavage sites so that the cloned target gene product can be released from the GST moiety.

[0053] In an insect system, Autographa californica nuclear polyhidrosis virus (AcNPV) is used as a vector to express foreign genes. The virus grows in Spodoptera frugiperda cells. A NHP coding sequence may be cloned individually into non-essential regions (for example the polyhedrin gene) of the virus and placed under control of an AcNPV promoter (for example the polyhedrin promoter). Successful insertion of NHP coding sequence will result in inactivation of the polyhedrin gene and production of non-occluded recombinant virus (i.e., virus lacking the proteinaceous coat coded for by the polyhedrin gene). These recombinant viruses are then used to infect Spodoptera frugiperda cells in which the inserted sequence is expressed (e.g., see Smith et al., 1983, J. Virol. 46:584; Smith, U.S. Pat. No. 4,215,051).

[0054] In mammalian host cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, the NHP nucleotide sequence of interest may be ligated to an adenovirus transcription/translation control complex, e.g., the late promoter and tripartite leader sequence. This chimeric gene may then be inserted in the adenovirus genome by in vitro or in vivo recombination. Insertion in a non-essential region of the viral genome (e.g., region E1 or E3) will result in a recombinant virus that is viable and capable of expressing a NHP product in infected hosts (e.g., See Logan & Shenk, 1984, Proc. Natl. Acad. Sci. USA 81:3655-3659). Specific initiation signals may also be required for efficient translation of inserted NHP nucleotide sequences. These signals include the ATG initiation codon and adjacent sequences. In cases where an entire NHP gene or cDNA, including its own initiation codon and adjacent sequences, is inserted into the appropriate expression vector, no additional translational control signals may be needed. However, in cases where only a portion of a NHP coding sequence is inserted, exogenous translational control signals, including, perhaps, the ATG initiation codon, must be provided. Furthermore, the initiation codon must be in phase with the reading frame of the desired coding sequence to ensure translation of the entire insert. These exogenous translational control signals and initiation codons can be of a variety of origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of appropriate transcription enhancer elements, transcription terminators, etc. (See Bitter et al., 1987, Methods in Enzymol. 153:516-544).

[0055] In addition, a host cell strain may be chosen that modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Such modifications (e.g., glycosylation) and processing (e.g., cleavage) of protein products may be important for the function of the protein. Different host cells have characteristic and specific mechanisms for the post-translational processing and modification of proteins and gene products. Appropriate cell lines or host systems can be chosen to ensure the correct modification and processing of the foreign protein expressed. To this end, eukaryotic host cells which possess the cellular machinery for proper processing of the primary transcript, glycosylation, and phosphorylation of the gene product may be used. Such mammalian host cells include, but are not limited to, CHO, VERO, BHK, HeLa, COS, MDCK, 293, 3T3, WI38, and in particular, human cell lines.

[0056] For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines which stably express the NHP sequences described above can be engineered. Rather than using expression vectors which contain viral origins of replication, host cells can be transformed with DNA controlled by appropriate expression control elements (e.g., promoter, enhancer sequences, transcription terminators, polyadenylation sites, etc.), and a selectable marker. Following the introduction of the foreign DNA, engineered cells may be allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media. The selectable marker in the recombinant plasmid confers resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci which in turn can be cloned and expanded into cell lines. This method may advantageously be used to engineer cell lines which express the NHP product. Such engineered cell lines may be particularly useful in screening and evaluation of compounds that affect the endogenous activity of the NHP product.

[0057] A number of selection systems may be used, including but not limited to the herpes simplex virus thymidine kinase (Wigler, et al., 1977, Cell 11:223), hypoxanthine-guanine phosphoribosyltransferase (Szybalska & Szybalski, 1962, Proc. Natl. Acad. Sci. USA 48:2026), and adenine phosphoribosyltransferase (Lowy, et al., 1980, Cell 22:817) genes can be employed in tk⁻, hgprt⁻ or aprt⁻ cells, respectively. Also, antimetabolite resistance can be used as the basis of selection for the following genes: dhfr, which confers resistance to methotrexate (Wigler, et al., 1980, Natl. Acad. Sci. USA 77:3567; O'Hare, et al., 1981, Proc. Natl. Acad. Sci. USA 78:1527); gpt, which confers resistance to mycophenolic acid (Mulligan & Berg, 1981, Proc. Natl. Acad. Sci. USA 78:2072); neo, which confers resistance to the aminoglycoside G-418 (Colberre-Garapin, et al., 1981, J. Mol. Biol. 150:1); and hygro, which confers resistance to hygromycin (Santerre, et al., 1984, Gene 30:147).

[0058] Alternatively, any fusion protein can be readily purified by utilizing an antibody specific for the fusion protein being expressed. For example, a system described by Janknecht et al. allows for the ready purification of non-denatured fusion proteins expressed in human cell lines (Janknecht, et al., 1991, Proc. Natl. Acad. Sci. USA 88:8972-8976). In this system, the gene of interest is subcloned into a vaccinia recombination plasmid such that the gene's open reading frame is translationally fused to an amino-terminal tag consisting of six histidine residues. Extracts from cells infected with recombinant vaccinia virus are loaded onto Ni²+ nitriloacetic acid-agarose columns and histidine-tagged proteins are selectively eluted with imidazole-containing buffers.

[0059] Also encompassed by the present invention are fusion proteins that direct the NHP to a target organ and/or facilitate transport across the membrane into the cytosol. Conjugation of NHPs to antibody molecules or their Fab fragments could be used to target cells bearing a particular epitope. Attaching the appropriate signal sequence to the NHP would also transport the NHP to the desired location within the cell. Alternatively targeting of NHP or its nucleic acid sequence might be achieved using liposome or lipid complex based delivery systems. Such technologies are described in Liposomes:A Practical Approach, New,RRC ed., Oxford University Press, New York and in U.S. Patents Nos. 4,594,595, 5,459,127, 5,948,767 and 6,110,490 and their respective disclosures which are herein incorporated by reference in their entirety. Additionally embodied are novel protein constructs engineered in such a way that they facilitate transport of the NHP to the target site or desired organ. This goal may be achieved by coupling of the NHP to a cytokine or other ligand that provides targeting specificity, and/or to a protein transducing domain (see generally U.S. applications Ser. Nos. 60/111,701 and 60/056,713, both of which are herein incorporated by reference, for examples of such transducing sequences) to facilitate passage across cellular membranes if needed and can optionally be engineered to include nuclear localization sequences when desired.

ANTIBODIES TO NHP PRODUCTS

[0060] Antibodies that specifically recognize one or more epitopes of a NHP, or epitopes of conserved variants of a NHP, or peptide fragments of a NHP are also encompassed by the invention. Such antibodies include but are not limited to polyclonal antibodies, monoclonal antibodies (mAbs), humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab′)₂ fragments, fragments produced by a Fab expression library, anti-idiotypic (anti-Id) antibodies, and epitope-binding fragments of any of the above.

[0061] The antibodies of the invention may be used, for example, in the detection of NHP in a biological sample and may, therefore, be utilized as part of a diagnostic or prognostic technique whereby patients may be tested for abnormal amounts of NHP. Such antibodies may also be utilized in conjunction with, for example, compound screening schemes for the evaluation of the effect of test compounds on expression and/or activity of a NHP gene product. Additionally, such antibodies can be used in conjunction gene therapy to, for example, evaluate the normal and/or engineered NHP-expressing cells prior to their introduction into the patient. Such antibodies may additionally be used as a method for the inhibition of abnormal NHP activity. Thus, such antibodies may, therefore, be utilized as part of treatment methods.

[0062] For the production of antibodies, various host animals may be immunized by injection with a NHP, an NHP peptide (e.g., one corresponding to a functional domain of an NHP), truncated NHP polypeptides (NHP in which one or more domains have been deleted), functional equivalents of the NHP or mutated variant of the NHP. Such host animals may include but are not limited to pigs, rabbits, mice, goats, and rats, to name but a few. Various adjuvants may be used to increase the immunological response, depending on the host species, including but not limited to Freund's adjuvant (complete and incomplete), mineral salts such as aluminum hydroxide or aluminum phosphate, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, and potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and Corynebacterium parvum. Alternatively, the immune response could be enhanced by combination and or coupling with molecules such as keyhole limpet hemocyanin, tetanus toxoid, diptheria toxoid, ovalbumin, cholera toxin or fragments thereof. Polyclonal antibodies are heterogeneous populations of antibody molecules derived from the sera of the immunized animals.

[0063] Monoclonal antibodies, which are homogeneous populations of antibodies to a particular antigen, can be obtained by any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique of Kohler and Milstein, (1975, Nature 256:495-497; and U.S. Pat. No. 4,376,110), the human B-cell hybridoma technique (Kosbor et al., 1983, Immunology Today 4:72; Cole et al., 1983, Proc. Natl. Acad. Sci. USA 80:2026-2030), and the EBV-hybridoma technique (Cole et al., 1985, Monoclonal Antibodies And Cancer Therapy, Alan R. Liss, Inc., pp. 77-96). Such antibodies may be of any immunoglobulin class including IgG, IgM, IgE, IgA, IgD and any subclass thereof. The hybridoma producing the mAb of this invention may be cultivated in vitro or in vivo. Production of high titers of mabs in vivo makes this the presently preferred method of production.

[0064] In addition, techniques developed for the production of “chimeric antibodies” (Morrison et al., 1984, Proc. Natl. Acad. Sci., 81:6851-6855; Neuberger et al., 1984, Nature, 312:604-608; Takeda et al., 1985, Nature, 314:452-454) by splicing the genes from a mouse antibody molecule of appropriate antigen specificity together with genes from a human antibody molecule of appropriate biological activity can be used. A chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable region derived from a murine mAb and a human immunoglobulin constant region. Such technologies are described in U.S. Patents Nos. 6,075,181 and 5,877,397 and their respective disclosures which are herein incorporated by reference in their entirety. Also encompassed by the present invention is the use of fully humanized monoclonal antibodies as described in U.S. Pat. No. 6,150,584 and respective disclosures which are herein incorporated by reference in their entirety.

[0065] Alternatively, techniques described for the production of single chain antibodies (U.S. Pat. No. 4,946,778; Bird, 1988, Science 242:423-426; Huston et al., 1988, Proc. Natl. Acad. Sci. USA 85:5879-5883; and Ward et al., 1989, Nature 341:544-546) can be adapted to produce single chain antibodies against NHP gene products. Single chain antibodies are formed by linking the heavy and light chain fragments of the Fv region via an amino acid bridge, resulting in a single chain polypeptide.

[0066] Antibody fragments which recognize specific epitopes may be generated by known techniques. For example, such fragments include, but are not limited to: the F(ab′)₂ fragments which can be produced by pepsin digestion of the antibody molecule and the Fab fragments which can be generated by reducing the disulfide bridges of the F(ab′)₂ fragments. Alternatively, Fab expression libraries may be constructed (Huse et al., 1989, Science, 246:1275-1281) to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity.

[0067] Antibodies to a NHP can, in turn, be utilized to generate anti-idiotype antibodies that “mimic” a given NHP, using techniques well known to those skilled in the art. (See, e.g., Greenspan & Bona, 1993, FASEB J 7(5):437-444; and Nissinoff, 1991, J. Immunol. 147(8):2429-2438). For example antibodies which bind to a NHP domain and competitively inhibit the binding of NHP to its cognate receptor can be used to generate anti-idiotypes that “mimic” the NHP and, therefore, bind and activate or neutralize a receptor. Such anti-idiotypic antibodies or Fab fragments of such anti-idiotypes can be used in therapeutic regimens involving a NHP mediated pathway.

[0068] The present invention is not to be limited in scope by the specific embodiments described herein, which are intended as single illustrations of individual aspects of the invention, and functionally equivalent methods and components are within the scope of the invention. Indeed, various modifications of the invention, in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description. Such modifications are intended to fall within the scope of the appended claims. All cited publications, patents, and patent applications are herein incorporated by reference in their entirety.

1 40 1 1311 DNA Homo sapiens 1 atgcagccac ccccagacga ggcccgcagg gacatggccg gggacaccca gtggtccagg 60 cccgagtgcc aggcatggac ggggacgctg ctgctgggca cgtgccttct gtactgcgcc 120 cgctccagca tgcccatctg caccgtctcc atgagccagg acttcggctg gaacaagaag 180 gaggccggca tcgtgctcag cagcttcttc tggggctact gcctgacaca ggttgtgggc 240 ggccacctcg gggatcggat tgggggtgag aaggtcatcc tgctgtcagc ctctgcctgg 300 ggctccatca cggccgtcac cccactgctc gcccacctga gcagtgccca cctggccttc 360 atgaccttct cacgcatcct catgggcttg ctccaagggg tttacttccc tgccctgacc 420 agcctgctgt cgcagaaggt gcgggagagt gagcgagcct tcacctacag catcgtgggc 480 gccggctccc agtttgggac gctgctgacc ggggcggtgg gctccctgct cctggaatgg 540 tacggctggc agagcatctt ctatttctcc ggcggcctca ccttgctttg ggtgtggtac 600 gtgtacaggt acctgctgag tgaaaaagat ctcatcctgg ccttgggtgt cctggcccaa 660 agccggccgg tgtccaggca cagcagagtc ccctggagac ggctcttccg gaagcctgct 720 gtctgggcag ccgtcgtctc ccagctctct gcagcctgct ccttcttcat cctcctctcc 780 tggctgccca ccttcttcga ggagaccttc cccgacgcca agggctggat cttcaacgtg 840 gttccttggt tggtggcgat tccggccagt ctattcagcg ggtttctctc tgatcatctc 900 atcaatcagg gttacagagc catcacggtg cggaagctca tgcagggcat gggccttggc 960 ctctccagcg tctttgctct gtgcctgggc cacacctcca gcttctgtga gtctgtggtc 1020 tttgcatcag cctccatcgg cctccagacc ttcaaccaca gtggcatttc tgttaacatc 1080 caggacttgg ccccgtcctg cgccggcttt ctgtttggtg tggccaacac agccggggcc 1140 ttggcaggtg tcgtgggtgt gtgtctaggc ggctacttga tggagaccac gggctcctgg 1200 acttgcctgt tcaaccttgt ggccatcatc agcaacctgg ggctgtgcac cttcctggtg 1260 tttggacagg ctcagagggt ggacctgagc tctacccatg aggacctcta g 1311 2 436 PRT Homo sapiens 2 Met Gln Pro Pro Pro Asp Glu Ala Arg Arg Asp Met Ala Gly Asp Thr 1 5 10 15 Gln Trp Ser Arg Pro Glu Cys Gln Ala Trp Thr Gly Thr Leu Leu Leu 20 25 30 Gly Thr Cys Leu Leu Tyr Cys Ala Arg Ser Ser Met Pro Ile Cys Thr 35 40 45 Val Ser Met Ser Gln Asp Phe Gly Trp Asn Lys Lys Glu Ala Gly Ile 50 55 60 Val Leu Ser Ser Phe Phe Trp Gly Tyr Cys Leu Thr Gln Val Val Gly 65 70 75 80 Gly His Leu Gly Asp Arg Ile Gly Gly Glu Lys Val Ile Leu Leu Ser 85 90 95 Ala Ser Ala Trp Gly Ser Ile Thr Ala Val Thr Pro Leu Leu Ala His 100 105 110 Leu Ser Ser Ala His Leu Ala Phe Met Thr Phe Ser Arg Ile Leu Met 115 120 125 Gly Leu Leu Gln Gly Val Tyr Phe Pro Ala Leu Thr Ser Leu Leu Ser 130 135 140 Gln Lys Val Arg Glu Ser Glu Arg Ala Phe Thr Tyr Ser Ile Val Gly 145 150 155 160 Ala Gly Ser Gln Phe Gly Thr Leu Leu Thr Gly Ala Val Gly Ser Leu 165 170 175 Leu Leu Glu Trp Tyr Gly Trp Gln Ser Ile Phe Tyr Phe Ser Gly Gly 180 185 190 Leu Thr Leu Leu Trp Val Trp Tyr Val Tyr Arg Tyr Leu Leu Ser Glu 195 200 205 Lys Asp Leu Ile Leu Ala Leu Gly Val Leu Ala Gln Ser Arg Pro Val 210 215 220 Ser Arg His Ser Arg Val Pro Trp Arg Arg Leu Phe Arg Lys Pro Ala 225 230 235 240 Val Trp Ala Ala Val Val Ser Gln Leu Ser Ala Ala Cys Ser Phe Phe 245 250 255 Ile Leu Leu Ser Trp Leu Pro Thr Phe Phe Glu Glu Thr Phe Pro Asp 260 265 270 Ala Lys Gly Trp Ile Phe Asn Val Val Pro Trp Leu Val Ala Ile Pro 275 280 285 Ala Ser Leu Phe Ser Gly Phe Leu Ser Asp His Leu Ile Asn Gln Gly 290 295 300 Tyr Arg Ala Ile Thr Val Arg Lys Leu Met Gln Gly Met Gly Leu Gly 305 310 315 320 Leu Ser Ser Val Phe Ala Leu Cys Leu Gly His Thr Ser Ser Phe Cys 325 330 335 Glu Ser Val Val Phe Ala Ser Ala Ser Ile Gly Leu Gln Thr Phe Asn 340 345 350 His Ser Gly Ile Ser Val Asn Ile Gln Asp Leu Ala Pro Ser Cys Ala 355 360 365 Gly Phe Leu Phe Gly Val Ala Asn Thr Ala Gly Ala Leu Ala Gly Val 370 375 380 Val Gly Val Cys Leu Gly Gly Tyr Leu Met Glu Thr Thr Gly Ser Trp 385 390 395 400 Thr Cys Leu Phe Asn Leu Val Ala Ile Ile Ser Asn Leu Gly Leu Cys 405 410 415 Thr Phe Leu Val Phe Gly Gln Ala Gln Arg Val Asp Leu Ser Ser Thr 420 425 430 His Glu Asp Leu 435 3 1179 DNA Homo sapiens 3 atgaccctga caagcaggcg ccaggacagt caggaggcca ggcccgagtg ccaggcatgg 60 acggggacgc tgctgctggg cacgtgcctt ctgtactgcg cccgctccag catgcccatc 120 tgcaccgtct ccatgagcca ggacttcggc tggaacaaga aggaggccgg catcgtgctc 180 agcagcttct tctggggcta ctgcctgaca caggttgtgg gcggccacct cggggatcgg 240 attgggggtg agaaggtcat cctgctgtca gcctctgcct ggggctccat cacggccgtc 300 accccactgc tcgcccacct gagcagtgcc cacctggcct tcatgacctt ctcacgcatc 360 ctcatgggct tgctccaagg ggtttacttc cctgccctga ccagcctgct gtcgcagaag 420 gtgcgggaga gtgagcgagc cttcacctac agcatcgtgg gcgccggctc ccagtttggg 480 acgctgctga ccggggcggt gggctccctg ctcctggaat ggtacggctg gcagagcatc 540 ttctatttct ccggcggcct caccttgctt tgggtgtggt acgtgtacag gtacctgctg 600 agtgaaaaag atctcatcct ggccttgggt gtcctggccc aaagccggcc ggtgtccagg 660 cacagcagag tcccctggag acggctcttc cggaagcctg ctgtctgggc agccgtcgtc 720 tcccagctct ctgcagcctg ctccttcttc atcctcctct cctggctgcc caccttcttc 780 gaggagacct tccccgacgc caagggctgg atcttcaacg tggttccttg gttggtggcg 840 attccggcca gtctattcag cgggtttctc tctgatcatc tcatcaatca gggttacaga 900 gccatcacgg tgcggaagct catgcagggc atgggccttg gcctctccag cgtctttgct 960 ctgtgcctgg gccacacctc cagcttctgt gagtctgtgg tctttgcatc agcctccatc 1020 ggcctccaga ccttcaacca cagtggcatt tctgttaaca tccaggactt ggccccgtcc 1080 tgcgccggct ttctgtttgg tgtggccaac acagccgggg ccttggcagg tgaggggcgg 1140 gcctctgtgc ccaggagttc ccctgtctgt ggggtttga 1179 4 392 PRT Homo sapiens 4 Met Thr Leu Thr Ser Arg Arg Gln Asp Ser Gln Glu Ala Arg Pro Glu 1 5 10 15 Cys Gln Ala Trp Thr Gly Thr Leu Leu Leu Gly Thr Cys Leu Leu Tyr 20 25 30 Cys Ala Arg Ser Ser Met Pro Ile Cys Thr Val Ser Met Ser Gln Asp 35 40 45 Phe Gly Trp Asn Lys Lys Glu Ala Gly Ile Val Leu Ser Ser Phe Phe 50 55 60 Trp Gly Tyr Cys Leu Thr Gln Val Val Gly Gly His Leu Gly Asp Arg 65 70 75 80 Ile Gly Gly Glu Lys Val Ile Leu Leu Ser Ala Ser Ala Trp Gly Ser 85 90 95 Ile Thr Ala Val Thr Pro Leu Leu Ala His Leu Ser Ser Ala His Leu 100 105 110 Ala Phe Met Thr Phe Ser Arg Ile Leu Met Gly Leu Leu Gln Gly Val 115 120 125 Tyr Phe Pro Ala Leu Thr Ser Leu Leu Ser Gln Lys Val Arg Glu Ser 130 135 140 Glu Arg Ala Phe Thr Tyr Ser Ile Val Gly Ala Gly Ser Gln Phe Gly 145 150 155 160 Thr Leu Leu Thr Gly Ala Val Gly Ser Leu Leu Leu Glu Trp Tyr Gly 165 170 175 Trp Gln Ser Ile Phe Tyr Phe Ser Gly Gly Leu Thr Leu Leu Trp Val 180 185 190 Trp Tyr Val Tyr Arg Tyr Leu Leu Ser Glu Lys Asp Leu Ile Leu Ala 195 200 205 Leu Gly Val Leu Ala Gln Ser Arg Pro Val Ser Arg His Ser Arg Val 210 215 220 Pro Trp Arg Arg Leu Phe Arg Lys Pro Ala Val Trp Ala Ala Val Val 225 230 235 240 Ser Gln Leu Ser Ala Ala Cys Ser Phe Phe Ile Leu Leu Ser Trp Leu 245 250 255 Pro Thr Phe Phe Glu Glu Thr Phe Pro Asp Ala Lys Gly Trp Ile Phe 260 265 270 Asn Val Val Pro Trp Leu Val Ala Ile Pro Ala Ser Leu Phe Ser Gly 275 280 285 Phe Leu Ser Asp His Leu Ile Asn Gln Gly Tyr Arg Ala Ile Thr Val 290 295 300 Arg Lys Leu Met Gln Gly Met Gly Leu Gly Leu Ser Ser Val Phe Ala 305 310 315 320 Leu Cys Leu Gly His Thr Ser Ser Phe Cys Glu Ser Val Val Phe Ala 325 330 335 Ser Ala Ser Ile Gly Leu Gln Thr Phe Asn His Ser Gly Ile Ser Val 340 345 350 Asn Ile Gln Asp Leu Ala Pro Ser Cys Ala Gly Phe Leu Phe Gly Val 355 360 365 Ala Asn Thr Ala Gly Ala Leu Ala Gly Glu Gly Arg Ala Ser Val Pro 370 375 380 Arg Ser Ser Pro Val Cys Gly Val 385 390 5 1197 DNA Homo sapiens 5 atgcagccac ccccagacga ggcccgcagg gacatggccg gggacaccca gtggtccagg 60 cccgagtgcc aggcatggac ggggacgctg ctgctgggca cgtgccttct gtactgcgcc 120 cgctccagca tgcccatctg caccgtctcc atgagccagg acttcggctg gaacaagaag 180 gaggccggca tcgtgctcag cagcttcttc tggggctact gcctgacaca ggttgtgggc 240 ggccacctcg gggatcggat tgggggtgag aaggtcatcc tgctgtcagc ctctgcctgg 300 ggctccatca cggccgtcac cccactgctc gcccacctga gcagtgccca cctggccttc 360 atgaccttct cacgcatcct catgggcttg ctccaagggg tttacttccc tgccctgacc 420 agcctgctgt cgcagaaggt gcgggagagt gagcgagcct tcacctacag catcgtgggc 480 gccggctccc agtttgggac gctgctgacc ggggcggtgg gctccctgct cctggaatgg 540 tacggctggc agagcatctt ctatttctcc ggcggcctca ccttgctttg ggtgtggtac 600 gtgtacaggt acctgctgag tgaaaaagat ctcatcctgg ccttgggtgt cctggcccaa 660 agccggccgg tgtccaggca cagcagagtc ccctggagac ggctcttccg gaagcctgct 720 gtctgggcag ccgtcgtctc ccagctctct gcagcctgct ccttcttcat cctcctctcc 780 tggctgccca ccttcttcga ggagaccttc cccgacgcca agggctggat cttcaacgtg 840 gttccttggt tggtggcgat tccggccagt ctattcagcg ggtttctctc tgatcatctc 900 atcaatcagg gttacagagc catcacggtg cggaagctca tgcagggcat gggccttggc 960 ctctccagcg tctttgctct gtgcctgggc cacacctcca gcttctgtga gtctgtggtc 1020 tttgcatcag cctccatcgg cctccagacc ttcaaccaca gtggcatttc tgttaacatc 1080 caggacttgg ccccgtcctg cgccggcttt ctgtttggtg tggccaacac agccggggcc 1140 ttggcaggtg aggggcgggc ctctgtgccc aggagttccc ctgtctgtgg ggtttga 1197 6 398 PRT Homo sapiens 6 Met Gln Pro Pro Pro Asp Glu Ala Arg Arg Asp Met Ala Gly Asp Thr 1 5 10 15 Gln Trp Ser Arg Pro Glu Cys Gln Ala Trp Thr Gly Thr Leu Leu Leu 20 25 30 Gly Thr Cys Leu Leu Tyr Cys Ala Arg Ser Ser Met Pro Ile Cys Thr 35 40 45 Val Ser Met Ser Gln Asp Phe Gly Trp Asn Lys Lys Glu Ala Gly Ile 50 55 60 Val Leu Ser Ser Phe Phe Trp Gly Tyr Cys Leu Thr Gln Val Val Gly 65 70 75 80 Gly His Leu Gly Asp Arg Ile Gly Gly Glu Lys Val Ile Leu Leu Ser 85 90 95 Ala Ser Ala Trp Gly Ser Ile Thr Ala Val Thr Pro Leu Leu Ala His 100 105 110 Leu Ser Ser Ala His Leu Ala Phe Met Thr Phe Ser Arg Ile Leu Met 115 120 125 Gly Leu Leu Gln Gly Val Tyr Phe Pro Ala Leu Thr Ser Leu Leu Ser 130 135 140 Gln Lys Val Arg Glu Ser Glu Arg Ala Phe Thr Tyr Ser Ile Val Gly 145 150 155 160 Ala Gly Ser Gln Phe Gly Thr Leu Leu Thr Gly Ala Val Gly Ser Leu 165 170 175 Leu Leu Glu Trp Tyr Gly Trp Gln Ser Ile Phe Tyr Phe Ser Gly Gly 180 185 190 Leu Thr Leu Leu Trp Val Trp Tyr Val Tyr Arg Tyr Leu Leu Ser Glu 195 200 205 Lys Asp Leu Ile Leu Ala Leu Gly Val Leu Ala Gln Ser Arg Pro Val 210 215 220 Ser Arg His Ser Arg Val Pro Trp Arg Arg Leu Phe Arg Lys Pro Ala 225 230 235 240 Val Trp Ala Ala Val Val Ser Gln Leu Ser Ala Ala Cys Ser Phe Phe 245 250 255 Ile Leu Leu Ser Trp Leu Pro Thr Phe Phe Glu Glu Thr Phe Pro Asp 260 265 270 Ala Lys Gly Trp Ile Phe Asn Val Val Pro Trp Leu Val Ala Ile Pro 275 280 285 Ala Ser Leu Phe Ser Gly Phe Leu Ser Asp His Leu Ile Asn Gln Gly 290 295 300 Tyr Arg Ala Ile Thr Val Arg Lys Leu Met Gln Gly Met Gly Leu Gly 305 310 315 320 Leu Ser Ser Val Phe Ala Leu Cys Leu Gly His Thr Ser Ser Phe Cys 325 330 335 Glu Ser Val Val Phe Ala Ser Ala Ser Ile Gly Leu Gln Thr Phe Asn 340 345 350 His Ser Gly Ile Ser Val Asn Ile Gln Asp Leu Ala Pro Ser Cys Ala 355 360 365 Gly Phe Leu Phe Gly Val Ala Asn Thr Ala Gly Ala Leu Ala Gly Glu 370 375 380 Gly Arg Ala Ser Val Pro Arg Ser Ser Pro Val Cys Gly Val 385 390 395 7 855 DNA Homo sapiens 7 atgaccctga caagcaggcg ccaggacagt caggaggcca ggcccgagtg ccaggcatgg 60 acggggacgc tgctgctggg cacgtgcctt ctgtactgcg cccgctccag catgcccatc 120 tgcaccgtct ccatgagcca ggacttcggc tggaacaaga aggaggccgg catcgtgctc 180 agcagcttct tctggggcta ctgcctgaca caggttgtgg gcggccacct cggggatcgg 240 attgggggtg agaaggtcat cctgctgtca gcctctgcct ggggctccat cacggccgtc 300 accccactgc tcgcccacct gagcagtgcc cacctggcct tcatgacctt ctcacgcatc 360 ctcatgggct tgctccaagg ggtttacttc cctgccctga ccagcctgct gtcgcagaag 420 gtgcgggaga gtgagcgagc cttcacctac agcatcgtgg gcgccggctc ccagtttggg 480 acgctgctga ccggggcggt gggctccctg ctcctggaat ggtacggctg gcagagcatc 540 ttctatttct ccggcggcct caccttgctt tgggtgtggt acgtgtacag atctcatcct 600 ggccttgggt gtcctggccc aaagccggcc ggtgtccagg cacagcagag tcccctggag 660 acggctcttc cggaagcctg ctgtctgggc agccgtcgtc tcccagctct ctgcagcctg 720 ctccttcttc atcctcctct cctggctgcc caccttcttc gaggagacct tccccgacgc 780 caagggctgg atcttcaacg tggttccttg gttggtggcg attccggcca gtctattcag 840 cgggtttctc tctga 855 8 284 PRT Homo sapiens 8 Met Thr Leu Thr Ser Arg Arg Gln Asp Ser Gln Glu Ala Arg Pro Glu 1 5 10 15 Cys Gln Ala Trp Thr Gly Thr Leu Leu Leu Gly Thr Cys Leu Leu Tyr 20 25 30 Cys Ala Arg Ser Ser Met Pro Ile Cys Thr Val Ser Met Ser Gln Asp 35 40 45 Phe Gly Trp Asn Lys Lys Glu Ala Gly Ile Val Leu Ser Ser Phe Phe 50 55 60 Trp Gly Tyr Cys Leu Thr Gln Val Val Gly Gly His Leu Gly Asp Arg 65 70 75 80 Ile Gly Gly Glu Lys Val Ile Leu Leu Ser Ala Ser Ala Trp Gly Ser 85 90 95 Ile Thr Ala Val Thr Pro Leu Leu Ala His Leu Ser Ser Ala His Leu 100 105 110 Ala Phe Met Thr Phe Ser Arg Ile Leu Met Gly Leu Leu Gln Gly Val 115 120 125 Tyr Phe Pro Ala Leu Thr Ser Leu Leu Ser Gln Lys Val Arg Glu Ser 130 135 140 Glu Arg Ala Phe Thr Tyr Ser Ile Val Gly Ala Gly Ser Gln Phe Gly 145 150 155 160 Thr Leu Leu Thr Gly Ala Val Gly Ser Leu Leu Leu Glu Trp Tyr Gly 165 170 175 Trp Gln Ser Ile Phe Tyr Phe Ser Gly Gly Leu Thr Leu Leu Trp Val 180 185 190 Trp Tyr Val Tyr Arg Ser His Pro Gly Leu Gly Cys Pro Gly Pro Lys 195 200 205 Pro Ala Gly Val Gln Ala Gln Gln Ser Pro Leu Glu Thr Ala Leu Pro 210 215 220 Glu Ala Cys Cys Leu Gly Ser Arg Arg Leu Pro Ala Leu Cys Ser Leu 225 230 235 240 Leu Leu Leu His Pro Pro Leu Leu Ala Ala His Leu Leu Arg Gly Asp 245 250 255 Leu Pro Arg Arg Gln Gly Leu Asp Leu Gln Arg Gly Ser Leu Val Gly 260 265 270 Gly Asp Ser Gly Gln Ser Ile Gln Arg Val Ser Leu 275 280 9 873 DNA Homo sapiens 9 atgcagccac ccccagacga ggcccgcagg gacatggccg gggacaccca gtggtccagg 60 cccgagtgcc aggcatggac ggggacgctg ctgctgggca cgtgccttct gtactgcgcc 120 cgctccagca tgcccatctg caccgtctcc atgagccagg acttcggctg gaacaagaag 180 gaggccggca tcgtgctcag cagcttcttc tggggctact gcctgacaca ggttgtgggc 240 ggccacctcg gggatcggat tgggggtgag aaggtcatcc tgctgtcagc ctctgcctgg 300 ggctccatca cggccgtcac cccactgctc gcccacctga gcagtgccca cctggccttc 360 atgaccttct cacgcatcct catgggcttg ctccaagggg tttacttccc tgccctgacc 420 agcctgctgt cgcagaaggt gcgggagagt gagcgagcct tcacctacag catcgtgggc 480 gccggctccc agtttgggac gctgctgacc ggggcggtgg gctccctgct cctggaatgg 540 tacggctggc agagcatctt ctatttctcc ggcggcctca ccttgctttg ggtgtggtac 600 gtgtacagat ctcatcctgg ccttgggtgt cctggcccaa agccggccgg tgtccaggca 660 cagcagagtc ccctggagac ggctcttccg gaagcctgct gtctgggcag ccgtcgtctc 720 ccagctctct gcagcctgct ccttcttcat cctcctctcc tggctgccca ccttcttcga 780 ggagaccttc cccgacgcca agggctggat cttcaacgtg gttccttggt tggtggcgat 840 tccggccagt ctattcagcg ggtttctctc tga 873 10 290 PRT Homo sapiens 10 Met Gln Pro Pro Pro Asp Glu Ala Arg Arg Asp Met Ala Gly Asp Thr 1 5 10 15 Gln Trp Ser Arg Pro Glu Cys Gln Ala Trp Thr Gly Thr Leu Leu Leu 20 25 30 Gly Thr Cys Leu Leu Tyr Cys Ala Arg Ser Ser Met Pro Ile Cys Thr 35 40 45 Val Ser Met Ser Gln Asp Phe Gly Trp Asn Lys Lys Glu Ala Gly Ile 50 55 60 Val Leu Ser Ser Phe Phe Trp Gly Tyr Cys Leu Thr Gln Val Val Gly 65 70 75 80 Gly His Leu Gly Asp Arg Ile Gly Gly Glu Lys Val Ile Leu Leu Ser 85 90 95 Ala Ser Ala Trp Gly Ser Ile Thr Ala Val Thr Pro Leu Leu Ala His 100 105 110 Leu Ser Ser Ala His Leu Ala Phe Met Thr Phe Ser Arg Ile Leu Met 115 120 125 Gly Leu Leu Gln Gly Val Tyr Phe Pro Ala Leu Thr Ser Leu Leu Ser 130 135 140 Gln Lys Val Arg Glu Ser Glu Arg Ala Phe Thr Tyr Ser Ile Val Gly 145 150 155 160 Ala Gly Ser Gln Phe Gly Thr Leu Leu Thr Gly Ala Val Gly Ser Leu 165 170 175 Leu Leu Glu Trp Tyr Gly Trp Gln Ser Ile Phe Tyr Phe Ser Gly Gly 180 185 190 Leu Thr Leu Leu Trp Val Trp Tyr Val Tyr Arg Ser His Pro Gly Leu 195 200 205 Gly Cys Pro Gly Pro Lys Pro Ala Gly Val Gln Ala Gln Gln Ser Pro 210 215 220 Leu Glu Thr Ala Leu Pro Glu Ala Cys Cys Leu Gly Ser Arg Arg Leu 225 230 235 240 Pro Ala Leu Cys Ser Leu Leu Leu Leu His Pro Pro Leu Leu Ala Ala 245 250 255 His Leu Leu Arg Gly Asp Leu Pro Arg Arg Gln Gly Leu Asp Leu Gln 260 265 270 Arg Gly Ser Leu Val Gly Gly Asp Ser Gly Gln Ser Ile Gln Arg Val 275 280 285 Ser Leu 290 11 1293 DNA Homo sapiens 11 atgaccctga caagcaggcg ccaggacagt caggaggcca ggcccgagtg ccaggcatgg 60 acggggacgc tgctgctggg cacgtgcctt ctgtactgcg cccgctccag catgcccatc 120 tgcaccgtct ccatgagcca ggacttcggc tggaacaaga aggaggccgg catcgtgctc 180 agcagcttct tctggggcta ctgcctgaca caggttgtgg gcggccacct cggggatcgg 240 attgggggtg agaaggtcat cctgctgtca gcctctgcct ggggctccat cacggccgtc 300 accccactgc tcgcccacct gagcagtgcc cacctggcct tcatgacctt ctcacgcatc 360 ctcatgggct tgctccaagg ggtttacttc cctgccctga ccagcctgct gtcgcagaag 420 gtgcgggaga gtgagcgagc cttcacctac agcatcgtgg gcgccggctc ccagtttggg 480 acgctgctga ccggggcggt gggctccctg ctcctggaat ggtacggctg gcagagcatc 540 ttctatttct ccggcggcct caccttgctt tgggtgtggt acgtgtacag gtacctgctg 600 agtgaaaaag atctcatcct ggccttgggt gtcctggccc aaagccggcc ggtgtccagg 660 cacagcagag tcccctggag acggctcttc cggaagcctg ctgtctgggc agccgtcgtc 720 tcccagctct ctgcagcctg ctccttcttc atcctcctct cctggctgcc caccttcttc 780 gaggagacct tccccgacgc caagggctgg atcttcaacg tggttccttg gttggtggcg 840 attccggcca gtctattcag cgggtttctc tctgatcatc tcatcaatca gggttacaga 900 gccatcacgg tgcggaagct catgcagggc atgggccttg gcctctccag cgtctttgct 960 ctgtgcctgg gccacacctc cagcttctgt gagtctgtgg tctttgcatc agcctccatc 1020 ggcctccaga ccttcaacca cagtggcatt tctgttaaca tccaggactt ggccccgtcc 1080 tgcgccggct ttctgtttgg tgtggccaac acagccgggg ccttggcagg tgtcgtgggt 1140 gtgtgtctag gcggctactt gatggagacc acgggctcct ggacttgcct gttcaacctt 1200 gtggccatca tcagcaacct ggggctgtgc accttcctgg tgtttggaca ggctcagagg 1260 gtggacctga gctctaccca tgaggacctc tag 1293 12 430 PRT Homo sapiens 12 Met Thr Leu Thr Ser Arg Arg Gln Asp Ser Gln Glu Ala Arg Pro Glu 1 5 10 15 Cys Gln Ala Trp Thr Gly Thr Leu Leu Leu Gly Thr Cys Leu Leu Tyr 20 25 30 Cys Ala Arg Ser Ser Met Pro Ile Cys Thr Val Ser Met Ser Gln Asp 35 40 45 Phe Gly Trp Asn Lys Lys Glu Ala Gly Ile Val Leu Ser Ser Phe Phe 50 55 60 Trp Gly Tyr Cys Leu Thr Gln Val Val Gly Gly His Leu Gly Asp Arg 65 70 75 80 Ile Gly Gly Glu Lys Val Ile Leu Leu Ser Ala Ser Ala Trp Gly Ser 85 90 95 Ile Thr Ala Val Thr Pro Leu Leu Ala His Leu Ser Ser Ala His Leu 100 105 110 Ala Phe Met Thr Phe Ser Arg Ile Leu Met Gly Leu Leu Gln Gly Val 115 120 125 Tyr Phe Pro Ala Leu Thr Ser Leu Leu Ser Gln Lys Val Arg Glu Ser 130 135 140 Glu Arg Ala Phe Thr Tyr Ser Ile Val Gly Ala Gly Ser Gln Phe Gly 145 150 155 160 Thr Leu Leu Thr Gly Ala Val Gly Ser Leu Leu Leu Glu Trp Tyr Gly 165 170 175 Trp Gln Ser Ile Phe Tyr Phe Ser Gly Gly Leu Thr Leu Leu Trp Val 180 185 190 Trp Tyr Val Tyr Arg Tyr Leu Leu Ser Glu Lys Asp Leu Ile Leu Ala 195 200 205 Leu Gly Val Leu Ala Gln Ser Arg Pro Val Ser Arg His Ser Arg Val 210 215 220 Pro Trp Arg Arg Leu Phe Arg Lys Pro Ala Val Trp Ala Ala Val Val 225 230 235 240 Ser Gln Leu Ser Ala Ala Cys Ser Phe Phe Ile Leu Leu Ser Trp Leu 245 250 255 Pro Thr Phe Phe Glu Glu Thr Phe Pro Asp Ala Lys Gly Trp Ile Phe 260 265 270 Asn Val Val Pro Trp Leu Val Ala Ile Pro Ala Ser Leu Phe Ser Gly 275 280 285 Phe Leu Ser Asp His Leu Ile Asn Gln Gly Tyr Arg Ala Ile Thr Val 290 295 300 Arg Lys Leu Met Gln Gly Met Gly Leu Gly Leu Ser Ser Val Phe Ala 305 310 315 320 Leu Cys Leu Gly His Thr Ser Ser Phe Cys Glu Ser Val Val Phe Ala 325 330 335 Ser Ala Ser Ile Gly Leu Gln Thr Phe Asn His Ser Gly Ile Ser Val 340 345 350 Asn Ile Gln Asp Leu Ala Pro Ser Cys Ala Gly Phe Leu Phe Gly Val 355 360 365 Ala Asn Thr Ala Gly Ala Leu Ala Gly Val Val Gly Val Cys Leu Gly 370 375 380 Gly Tyr Leu Met Glu Thr Thr Gly Ser Trp Thr Cys Leu Phe Asn Leu 385 390 395 400 Val Ala Ile Ile Ser Asn Leu Gly Leu Cys Thr Phe Leu Val Phe Gly 405 410 415 Gln Ala Gln Arg Val Asp Leu Ser Ser Thr His Glu Asp Leu 420 425 430 13 1311 DNA homo sapiens 13 atgcagccac ccccagacga ggcccgcagg gacatggccg gggacaccca gtggtccagg 60 cccgagtgcc aggcatggac ggggacgctg ctgctgggca cgtgccttct gtactgcgcc 120 cgctccagca tgcccatctg caccgtctcc atgagccagg acttcggctg gaacaagaag 180 gaggccggca tcgtgctcag cagcttcttc tggggctact gcctgacaca ggttgtgggc 240 ggccacctcg gggatcggat tgggggtgag aaggtcatcc tgctgtcagc ctctgcctgg 300 ggctccatca cggccgtcac cccactgctc gcccacctga gcagtgccca cctggccttc 360 atgaccttct cacgcatcct catgggcttg ctccaagggg tttacttccc tgccctgacc 420 agcctgctgt cgcagaaggt gcgggagagt gagcgagcct tcacctacag catcgtgggc 480 gccggctccc agtttgggac gctgctgacc ggggcggtgg gctccctgct cctggaatgg 540 tacggctggc agagcatctt ctatttctcc ggcggcctca ccttgctttg ggtgtggtac 600 gtgtacaggt acctgctgag tgaaaaagat ctcatcctgg ccttgggtgt cctggcccaa 660 agccggccgg tgtccaggca cagcagagtc ccctggagac ggctcttccg gaagcctgct 720 gtctgggcag ccgtcgtctc ccagctctct gcagcctgct ccttcttcat cctcctctcc 780 tggctgccca ccttcttcga ggagaccttc cccgacgcca agggctggat cttcaacgtg 840 gttccttggt tggtggcgat tccggccagt ctattcagcg ggtttctctc tgatcatctc 900 atcaatcagg gttacagagc catcacggtg cggaagctca tgcagggcat gggccttggc 960 ctctccagcg tctttgctct gtgcctgggc cacacctcca gcttctgtga gtctgtggtc 1020 tttgcatcag cctccatcgg cctccagacc ttcaaccaca gtggcatttc tgttaacatc 1080 caggacttgg ccccgtcctg cgccggcttt ctgtttggtg tggccaacac agccggggcc 1140 ttggcaggtg tcgtgggtgt gtgtctaggc ggctacttga tggagaccac gggctcctgg 1200 acttgcctgt tcaaccttgt ggccatcatc agcaacctgg ggctgtgcac cttcctggtg 1260 tttggacagg ctcagagggt ggacctgagc tctacccatg aggacctcta g 1311 14 436 PRT homo sapiens 14 Met Gln Pro Pro Pro Asp Glu Ala Arg Arg Asp Met Ala Gly Asp Thr 1 5 10 15 Gln Trp Ser Arg Pro Glu Cys Gln Ala Trp Thr Gly Thr Leu Leu Leu 20 25 30 Gly Thr Cys Leu Leu Tyr Cys Ala Arg Ser Ser Met Pro Ile Cys Thr 35 40 45 Val Ser Met Ser Gln Asp Phe Gly Trp Asn Lys Lys Glu Ala Gly Ile 50 55 60 Val Leu Ser Ser Phe Phe Trp Gly Tyr Cys Leu Thr Gln Val Val Gly 65 70 75 80 Gly His Leu Gly Asp Arg Ile Gly Gly Glu Lys Val Ile Leu Leu Ser 85 90 95 Ala Ser Ala Trp Gly Ser Ile Thr Ala Val Thr Pro Leu Leu Ala His 100 105 110 Leu Ser Ser Ala His Leu Ala Phe Met Thr Phe Ser Arg Ile Leu Met 115 120 125 Gly Leu Leu Gln Gly Val Tyr Phe Pro Ala Leu Thr Ser Leu Leu Ser 130 135 140 Gln Lys Val Arg Glu Ser Glu Arg Ala Phe Thr Tyr Ser Ile Val Gly 145 150 155 160 Ala Gly Ser Gln Phe Gly Thr Leu Leu Thr Gly Ala Val Gly Ser Leu 165 170 175 Leu Leu Glu Trp Tyr Gly Trp Gln Ser Ile Phe Tyr Phe Ser Gly Gly 180 185 190 Leu Thr Leu Leu Trp Val Trp Tyr Val Tyr Arg Tyr Leu Leu Ser Glu 195 200 205 Lys Asp Leu Ile Leu Ala Leu Gly Val Leu Ala Gln Ser Arg Pro Val 210 215 220 Ser Arg His Ser Arg Val Pro Trp Arg Arg Leu Phe Arg Lys Pro Ala 225 230 235 240 Val Trp Ala Ala Val Val Ser Gln Leu Ser Ala Ala Cys Ser Phe Phe 245 250 255 Ile Leu Leu Ser Trp Leu Pro Thr Phe Phe Glu Glu Thr Phe Pro Asp 260 265 270 Ala Lys Gly Trp Ile Phe Asn Val Val Pro Trp Leu Val Ala Ile Pro 275 280 285 Ala Ser Leu Phe Ser Gly Phe Leu Ser Asp His Leu Ile Asn Gln Gly 290 295 300 Tyr Arg Ala Ile Thr Val Arg Lys Leu Met Gln Gly Met Gly Leu Gly 305 310 315 320 Leu Ser Ser Val Phe Ala Leu Cys Leu Gly His Thr Ser Ser Phe Cys 325 330 335 Glu Ser Val Val Phe Ala Ser Ala Ser Ile Gly Leu Gln Thr Phe Asn 340 345 350 His Ser Gly Ile Ser Val Asn Ile Gln Asp Leu Ala Pro Ser Cys Ala 355 360 365 Gly Phe Leu Phe Gly Val Ala Asn Thr Ala Gly Ala Leu Ala Gly Val 370 375 380 Val Gly Val Cys Leu Gly Gly Tyr Leu Met Glu Thr Thr Gly Ser Trp 385 390 395 400 Thr Cys Leu Phe Asn Leu Val Ala Ile Ile Ser Asn Leu Gly Leu Cys 405 410 415 Thr Phe Leu Val Phe Gly Gln Ala Gln Arg Val Asp Leu Ser Ser Thr 420 425 430 His Glu Asp Leu 435 15 1179 DNA homo sapiens 15 atgaccctga caagcaggcg ccaggacagt caggaggcca ggcccgagtg ccaggcatgg 60 acggggacgc tgctgctggg cacgtgcctt ctgtactgcg cccgctccag catgcccatc 120 tgcaccgtct ccatgagcca ggacttcggc tggaacaaga aggaggccgg catcgtgctc 180 agcagcttct tctggggcta ctgcctgaca caggttgtgg gcggccacct cggggatcgg 240 attgggggtg agaaggtcat cctgctgtca gcctctgcct ggggctccat cacggccgtc 300 accccactgc tcgcccacct gagcagtgcc cacctggcct tcatgacctt ctcacgcatc 360 ctcatgggct tgctccaagg ggtttacttc cctgccctga ccagcctgct gtcgcagaag 420 gtgcgggaga gtgagcgagc cttcacctac agcatcgtgg gcgccggctc ccagtttggg 480 acgctgctga ccggggcggt gggctccctg ctcctggaat ggtacggctg gcagagcatc 540 ttctatttct ccggcggcct caccttgctt tgggtgtggt acgtgtacag gtacctgctg 600 agtgaaaaag atctcatcct ggccttgggt gtcctggccc aaagccggcc ggtgtccagg 660 cacagcagag tcccctggag acggctcttc cggaagcctg ctgtctgggc agccgtcgtc 720 tcccagctct ctgcagcctg ctccttcttc atcctcctct cctggctgcc caccttcttc 780 gaggagacct tccccgacgc caagggctgg atcttcaacg tggttccttg gttggtggcg 840 attccggcca gtctattcag cgggtttctc tctgatcatc tcatcaatca gggttacaga 900 gccatcacgg tgcggaagct catgcagggc atgggccttg gcctctccag cgtctttgct 960 ctgtgcctgg gccacacctc cagcttctgt gagtctgtgg tctttgcatc agcctccatc 1020 ggcctccaga ccttcaacca cagtggcatt tctgttaaca tccaggactt ggccccgtcc 1080 tgcgccggct ttctgtttgg tgtggccaac acagccgggg ccttggcagg tgaggggcgg 1140 gcctctgtgc ccaggagttc ccctgtctgt ggggtttga 1179 16 392 PRT homo sapiens 16 Met Thr Leu Thr Ser Arg Arg Gln Asp Ser Gln Glu Ala Arg Pro Glu 1 5 10 15 Cys Gln Ala Trp Thr Gly Thr Leu Leu Leu Gly Thr Cys Leu Leu Tyr 20 25 30 Cys Ala Arg Ser Ser Met Pro Ile Cys Thr Val Ser Met Ser Gln Asp 35 40 45 Phe Gly Trp Asn Lys Lys Glu Ala Gly Ile Val Leu Ser Ser Phe Phe 50 55 60 Trp Gly Tyr Cys Leu Thr Gln Val Val Gly Gly His Leu Gly Asp Arg 65 70 75 80 Ile Gly Gly Glu Lys Val Ile Leu Leu Ser Ala Ser Ala Trp Gly Ser 85 90 95 Ile Thr Ala Val Thr Pro Leu Leu Ala His Leu Ser Ser Ala His Leu 100 105 110 Ala Phe Met Thr Phe Ser Arg Ile Leu Met Gly Leu Leu Gln Gly Val 115 120 125 Tyr Phe Pro Ala Leu Thr Ser Leu Leu Ser Gln Lys Val Arg Glu Ser 130 135 140 Glu Arg Ala Phe Thr Tyr Ser Ile Val Gly Ala Gly Ser Gln Phe Gly 145 150 155 160 Thr Leu Leu Thr Gly Ala Val Gly Ser Leu Leu Leu Glu Trp Tyr Gly 165 170 175 Trp Gln Ser Ile Phe Tyr Phe Ser Gly Gly Leu Thr Leu Leu Trp Val 180 185 190 Trp Tyr Val Tyr Arg Tyr Leu Leu Ser Glu Lys Asp Leu Ile Leu Ala 195 200 205 Leu Gly Val Leu Ala Gln Ser Arg Pro Val Ser Arg His Ser Arg Val 210 215 220 Pro Trp Arg Arg Leu Phe Arg Lys Pro Ala Val Trp Ala Ala Val Val 225 230 235 240 Ser Gln Leu Ser Ala Ala Cys Ser Phe Phe Ile Leu Leu Ser Trp Leu 245 250 255 Pro Thr Phe Phe Glu Glu Thr Phe Pro Asp Ala Lys Gly Trp Ile Phe 260 265 270 Asn Val Val Pro Trp Leu Val Ala Ile Pro Ala Ser Leu Phe Ser Gly 275 280 285 Phe Leu Ser Asp His Leu Ile Asn Gln Gly Tyr Arg Ala Ile Thr Val 290 295 300 Arg Lys Leu Met Gln Gly Met Gly Leu Gly Leu Ser Ser Val Phe Ala 305 310 315 320 Leu Cys Leu Gly His Thr Ser Ser Phe Cys Glu Ser Val Val Phe Ala 325 330 335 Ser Ala Ser Ile Gly Leu Gln Thr Phe Asn His Ser Gly Ile Ser Val 340 345 350 Asn Ile Gln Asp Leu Ala Pro Ser Cys Ala Gly Phe Leu Phe Gly Val 355 360 365 Ala Asn Thr Ala Gly Ala Leu Ala Gly Glu Gly Arg Ala Ser Val Pro 370 375 380 Arg Ser Ser Pro Val Cys Gly Val 385 390 17 1197 DNA homo sapiens 17 atgcagccac ccccagacga ggcccgcagg gacatggccg gggacaccca gtggtccagg 60 cccgagtgcc aggcatggac ggggacgctg ctgctgggca cgtgccttct gtactgcgcc 120 cgctccagca tgcccatctg caccgtctcc atgagccagg acttcggctg gaacaagaag 180 gaggccggca tcgtgctcag cagcttcttc tggggctact gcctgacaca ggttgtgggc 240 ggccacctcg gggatcggat tgggggtgag aaggtcatcc tgctgtcagc ctctgcctgg 300 ggctccatca cggccgtcac cccactgctc gcccacctga gcagtgccca cctggccttc 360 atgaccttct cacgcatcct catgggcttg ctccaagggg tttacttccc tgccctgacc 420 agcctgctgt cgcagaaggt gcgggagagt gagcgagcct tcacctacag catcgtgggc 480 gccggctccc agtttgggac gctgctgacc ggggcggtgg gctccctgct cctggaatgg 540 tacggctggc agagcatctt ctatttctcc ggcggcctca ccttgctttg ggtgtggtac 600 gtgtacaggt acctgctgag tgaaaaagat ctcatcctgg ccttgggtgt cctggcccaa 660 agccggccgg tgtccaggca cagcagagtc ccctggagac ggctcttccg gaagcctgct 720 gtctgggcag ccgtcgtctc ccagctctct gcagcctgct ccttcttcat cctcctctcc 780 tggctgccca ccttcttcga ggagaccttc cccgacgcca agggctggat cttcaacgtg 840 gttccttggt tggtggcgat tccggccagt ctattcagcg ggtttctctc tgatcatctc 900 atcaatcagg gttacagagc catcacggtg cggaagctca tgcagggcat gggccttggc 960 ctctccagcg tctttgctct gtgcctgggc cacacctcca gcttctgtga gtctgtggtc 1020 tttgcatcag cctccatcgg cctccagacc ttcaaccaca gtggcatttc tgttaacatc 1080 caggacttgg ccccgtcctg cgccggcttt ctgtttggtg tggccaacac agccggggcc 1140 ttggcaggtg aggggcgggc ctctgtgccc aggagttccc ctgtctgtgg ggtttga 1197 18 398 PRT homo sapiens 18 Met Gln Pro Pro Pro Asp Glu Ala Arg Arg Asp Met Ala Gly Asp Thr 1 5 10 15 Gln Trp Ser Arg Pro Glu Cys Gln Ala Trp Thr Gly Thr Leu Leu Leu 20 25 30 Gly Thr Cys Leu Leu Tyr Cys Ala Arg Ser Ser Met Pro Ile Cys Thr 35 40 45 Val Ser Met Ser Gln Asp Phe Gly Trp Asn Lys Lys Glu Ala Gly Ile 50 55 60 Val Leu Ser Ser Phe Phe Trp Gly Tyr Cys Leu Thr Gln Val Val Gly 65 70 75 80 Gly His Leu Gly Asp Arg Ile Gly Gly Glu Lys Val Ile Leu Leu Ser 85 90 95 Ala Ser Ala Trp Gly Ser Ile Thr Ala Val Thr Pro Leu Leu Ala His 100 105 110 Leu Ser Ser Ala His Leu Ala Phe Met Thr Phe Ser Arg Ile Leu Met 115 120 125 Gly Leu Leu Gln Gly Val Tyr Phe Pro Ala Leu Thr Ser Leu Leu Ser 130 135 140 Gln Lys Val Arg Glu Ser Glu Arg Ala Phe Thr Tyr Ser Ile Val Gly 145 150 155 160 Ala Gly Ser Gln Phe Gly Thr Leu Leu Thr Gly Ala Val Gly Ser Leu 165 170 175 Leu Leu Glu Trp Tyr Gly Trp Gln Ser Ile Phe Tyr Phe Ser Gly Gly 180 185 190 Leu Thr Leu Leu Trp Val Trp Tyr Val Tyr Arg Tyr Leu Leu Ser Glu 195 200 205 Lys Asp Leu Ile Leu Ala Leu Gly Val Leu Ala Gln Ser Arg Pro Val 210 215 220 Ser Arg His Ser Arg Val Pro Trp Arg Arg Leu Phe Arg Lys Pro Ala 225 230 235 240 Val Trp Ala Ala Val Val Ser Gln Leu Ser Ala Ala Cys Ser Phe Phe 245 250 255 Ile Leu Leu Ser Trp Leu Pro Thr Phe Phe Glu Glu Thr Phe Pro Asp 260 265 270 Ala Lys Gly Trp Ile Phe Asn Val Val Pro Trp Leu Val Ala Ile Pro 275 280 285 Ala Ser Leu Phe Ser Gly Phe Leu Ser Asp His Leu Ile Asn Gln Gly 290 295 300 Tyr Arg Ala Ile Thr Val Arg Lys Leu Met Gln Gly Met Gly Leu Gly 305 310 315 320 Leu Ser Ser Val Phe Ala Leu Cys Leu Gly His Thr Ser Ser Phe Cys 325 330 335 Glu Ser Val Val Phe Ala Ser Ala Ser Ile Gly Leu Gln Thr Phe Asn 340 345 350 His Ser Gly Ile Ser Val Asn Ile Gln Asp Leu Ala Pro Ser Cys Ala 355 360 365 Gly Phe Leu Phe Gly Val Ala Asn Thr Ala Gly Ala Leu Ala Gly Glu 370 375 380 Gly Arg Ala Ser Val Pro Arg Ser Ser Pro Val Cys Gly Val 385 390 395 19 855 DNA homo sapiens 19 atgaccctga caagcaggcg ccaggacagt caggaggcca ggcccgagtg ccaggcatgg 60 acggggacgc tgctgctggg cacgtgcctt ctgtactgcg cccgctccag catgcccatc 120 tgcaccgtct ccatgagcca ggacttcggc tggaacaaga aggaggccgg catcgtgctc 180 agcagcttct tctggggcta ctgcctgaca caggttgtgg gcggccacct cggggatcgg 240 attgggggtg agaaggtcat cctgctgtca gcctctgcct ggggctccat cacggccgtc 300 accccactgc tcgcccacct gagcagtgcc cacctggcct tcatgacctt ctcacgcatc 360 ctcatgggct tgctccaagg ggtttacttc cctgccctga ccagcctgct gtcgcagaag 420 gtgcgggaga gtgagcgagc cttcacctac agcatcgtgg gcgccggctc ccagtttggg 480 acgctgctga ccggggcggt gggctccctg ctcctggaat ggtacggctg gcagagcatc 540 ttctatttct ccggcggcct caccttgctt tgggtgtggt acgtgtacag atctcatcct 600 ggccttgggt gtcctggccc aaagccggcc ggtgtccagg cacagcagag tcccctggag 660 acggctcttc cggaagcctg ctgtctgggc agccgtcgtc tcccagctct ctgcagcctg 720 ctccttcttc atcctcctct cctggctgcc caccttcttc gaggagacct tccccgacgc 780 caagggctgg atcttcaacg tggttccttg gttggtggcg attccggcca gtctattcag 840 cgggtttctc tctga 855 20 284 PRT homo sapiens 20 Met Thr Leu Thr Ser Arg Arg Gln Asp Ser Gln Glu Ala Arg Pro Glu 1 5 10 15 Cys Gln Ala Trp Thr Gly Thr Leu Leu Leu Gly Thr Cys Leu Leu Tyr 20 25 30 Cys Ala Arg Ser Ser Met Pro Ile Cys Thr Val Ser Met Ser Gln Asp 35 40 45 Phe Gly Trp Asn Lys Lys Glu Ala Gly Ile Val Leu Ser Ser Phe Phe 50 55 60 Trp Gly Tyr Cys Leu Thr Gln Val Val Gly Gly His Leu Gly Asp Arg 65 70 75 80 Ile Gly Gly Glu Lys Val Ile Leu Leu Ser Ala Ser Ala Trp Gly Ser 85 90 95 Ile Thr Ala Val Thr Pro Leu Leu Ala His Leu Ser Ser Ala His Leu 100 105 110 Ala Phe Met Thr Phe Ser Arg Ile Leu Met Gly Leu Leu Gln Gly Val 115 120 125 Tyr Phe Pro Ala Leu Thr Ser Leu Leu Ser Gln Lys Val Arg Glu Ser 130 135 140 Glu Arg Ala Phe Thr Tyr Ser Ile Val Gly Ala Gly Ser Gln Phe Gly 145 150 155 160 Thr Leu Leu Thr Gly Ala Val Gly Ser Leu Leu Leu Glu Trp Tyr Gly 165 170 175 Trp Gln Ser Ile Phe Tyr Phe Ser Gly Gly Leu Thr Leu Leu Trp Val 180 185 190 Trp Tyr Val Tyr Arg Ser His Pro Gly Leu Gly Cys Pro Gly Pro Lys 195 200 205 Pro Ala Gly Val Gln Ala Gln Gln Ser Pro Leu Glu Thr Ala Leu Pro 210 215 220 Glu Ala Cys Cys Leu Gly Ser Arg Arg Leu Pro Ala Leu Cys Ser Leu 225 230 235 240 Leu Leu Leu His Pro Pro Leu Leu Ala Ala His Leu Leu Arg Gly Asp 245 250 255 Leu Pro Arg Arg Gln Gly Leu Asp Leu Gln Arg Gly Ser Leu Val Gly 260 265 270 Gly Asp Ser Gly Gln Ser Ile Gln Arg Val Ser Leu 275 280 21 873 DNA homo sapiens 21 atgcagccac ccccagacga ggcccgcagg gacatggccg gggacaccca gtggtccagg 60 cccgagtgcc aggcatggac ggggacgctg ctgctgggca cgtgccttct gtactgcgcc 120 cgctccagca tgcccatctg caccgtctcc atgagccagg acttcggctg gaacaagaag 180 gaggccggca tcgtgctcag cagcttcttc tggggctact gcctgacaca ggttgtgggc 240 ggccacctcg gggatcggat tgggggtgag aaggtcatcc tgctgtcagc ctctgcctgg 300 ggctccatca cggccgtcac cccactgctc gcccacctga gcagtgccca cctggccttc 360 atgaccttct cacgcatcct catgggcttg ctccaagggg tttacttccc tgccctgacc 420 agcctgctgt cgcagaaggt gcgggagagt gagcgagcct tcacctacag catcgtgggc 480 gccggctccc agtttgggac gctgctgacc ggggcggtgg gctccctgct cctggaatgg 540 tacggctggc agagcatctt ctatttctcc ggcggcctca ccttgctttg ggtgtggtac 600 gtgtacagat ctcatcctgg ccttgggtgt cctggcccaa agccggccgg tgtccaggca 660 cagcagagtc ccctggagac ggctcttccg gaagcctgct gtctgggcag ccgtcgtctc 720 ccagctctct gcagcctgct ccttcttcat cctcctctcc tggctgccca ccttcttcga 780 ggagaccttc cccgacgcca agggctggat cttcaacgtg gttccttggt tggtggcgat 840 tccggccagt ctattcagcg ggtttctctc tga 873 22 290 PRT homo sapiens 22 Met Gln Pro Pro Pro Asp Glu Ala Arg Arg Asp Met Ala Gly Asp Thr 1 5 10 15 Gln Trp Ser Arg Pro Glu Cys Gln Ala Trp Thr Gly Thr Leu Leu Leu 20 25 30 Gly Thr Cys Leu Leu Tyr Cys Ala Arg Ser Ser Met Pro Ile Cys Thr 35 40 45 Val Ser Met Ser Gln Asp Phe Gly Trp Asn Lys Lys Glu Ala Gly Ile 50 55 60 Val Leu Ser Ser Phe Phe Trp Gly Tyr Cys Leu Thr Gln Val Val Gly 65 70 75 80 Gly His Leu Gly Asp Arg Ile Gly Gly Glu Lys Val Ile Leu Leu Ser 85 90 95 Ala Ser Ala Trp Gly Ser Ile Thr Ala Val Thr Pro Leu Leu Ala His 100 105 110 Leu Ser Ser Ala His Leu Ala Phe Met Thr Phe Ser Arg Ile Leu Met 115 120 125 Gly Leu Leu Gln Gly Val Tyr Phe Pro Ala Leu Thr Ser Leu Leu Ser 130 135 140 Gln Lys Val Arg Glu Ser Glu Arg Ala Phe Thr Tyr Ser Ile Val Gly 145 150 155 160 Ala Gly Ser Gln Phe Gly Thr Leu Leu Thr Gly Ala Val Gly Ser Leu 165 170 175 Leu Leu Glu Trp Tyr Gly Trp Gln Ser Ile Phe Tyr Phe Ser Gly Gly 180 185 190 Leu Thr Leu Leu Trp Val Trp Tyr Val Tyr Arg Ser His Pro Gly Leu 195 200 205 Gly Cys Pro Gly Pro Lys Pro Ala Gly Val Gln Ala Gln Gln Ser Pro 210 215 220 Leu Glu Thr Ala Leu Pro Glu Ala Cys Cys Leu Gly Ser Arg Arg Leu 225 230 235 240 Pro Ala Leu Cys Ser Leu Leu Leu Leu His Pro Pro Leu Leu Ala Ala 245 250 255 His Leu Leu Arg Gly Asp Leu Pro Arg Arg Gln Gly Leu Asp Leu Gln 260 265 270 Arg Gly Ser Leu Val Gly Gly Asp Ser Gly Gln Ser Ile Gln Arg Val 275 280 285 Ser Leu 290 23 1293 DNA homo sapiens 23 atgaccctga caagcaggcg ccaggacagt caggaggcca ggcccgagtg ccaggcatgg 60 acggggacgc tgctgctggg cacgtgcctt ctgtactgcg cccgctccag catgcccatc 120 tgcaccgtct ccatgagcca ggacttcggc tggaacaaga aggaggccgg catcgtgctc 180 agcagcttct tctggggcta ctgcctgaca caggttgtgg gcggccacct cggggatcgg 240 attgggggtg agaaggtcat cctgctgtca gcctctgcct ggggctccat cacggccgtc 300 accccactgc tcgcccacct gagcagtgcc cacctggcct tcatgacctt ctcacgcatc 360 ctcatgggct tgctccaagg ggtttacttc cctgccctga ccagcctgct gtcgcagaag 420 gtgcgggaga gtgagcgagc cttcacctac agcatcgtgg gcgccggctc ccagtttggg 480 acgctgctga ccggggcggt gggctccctg ctcctggaat ggtacggctg gcagagcatc 540 ttctatttct ccggcggcct caccttgctt tgggtgtggt acgtgtacag gtacctgctg 600 agtgaaaaag atctcatcct ggccttgggt gtcctggccc aaagccggcc ggtgtccagg 660 cacagcagag tcccctggag acggctcttc cggaagcctg ctgtctgggc agccgtcgtc 720 tcccagctct ctgcagcctg ctccttcttc atcctcctct cctggctgcc caccttcttc 780 gaggagacct tccccgacgc caagggctgg atcttcaacg tggttccttg gttggtggcg 840 attccggcca gtctattcag cgggtttctc tctgatcatc tcatcaatca gggttacaga 900 gccatcacgg tgcggaagct catgcagggc atgggccttg gcctctccag cgtctttgct 960 ctgtgcctgg gccacacctc cagcttctgt gagtctgtgg tctttgcatc agcctccatc 1020 ggcctccaga ccttcaacca cagtggcatt tctgttaaca tccaggactt ggccccgtcc 1080 tgcgccggct ttctgtttgg tgtggccaac acagccgggg ccttggcagg tgtcgtgggt 1140 gtgtgtctag gcggctactt gatggagacc acgggctcct ggacttgcct gttcaacctt 1200 gtggccatca tcagcaacct ggggctgtgc accttcctgg tgtttggaca ggctcagagg 1260 gtggacctga gctctaccca tgaggacctc tag 1293 24 430 PRT homo sapiens 24 Met Thr Leu Thr Ser Arg Arg Gln Asp Ser Gln Glu Ala Arg Pro Glu 1 5 10 15 Cys Gln Ala Trp Thr Gly Thr Leu Leu Leu Gly Thr Cys Leu Leu Tyr 20 25 30 Cys Ala Arg Ser Ser Met Pro Ile Cys Thr Val Ser Met Ser Gln Asp 35 40 45 Phe Gly Trp Asn Lys Lys Glu Ala Gly Ile Val Leu Ser Ser Phe Phe 50 55 60 Trp Gly Tyr Cys Leu Thr Gln Val Val Gly Gly His Leu Gly Asp Arg 65 70 75 80 Ile Gly Gly Glu Lys Val Ile Leu Leu Ser Ala Ser Ala Trp Gly Ser 85 90 95 Ile Thr Ala Val Thr Pro Leu Leu Ala His Leu Ser Ser Ala His Leu 100 105 110 Ala Phe Met Thr Phe Ser Arg Ile Leu Met Gly Leu Leu Gln Gly Val 115 120 125 Tyr Phe Pro Ala Leu Thr Ser Leu Leu Ser Gln Lys Val Arg Glu Ser 130 135 140 Glu Arg Ala Phe Thr Tyr Ser Ile Val Gly Ala Gly Ser Gln Phe Gly 145 150 155 160 Thr Leu Leu Thr Gly Ala Val Gly Ser Leu Leu Leu Glu Trp Tyr Gly 165 170 175 Trp Gln Ser Ile Phe Tyr Phe Ser Gly Gly Leu Thr Leu Leu Trp Val 180 185 190 Trp Tyr Val Tyr Arg Tyr Leu Leu Ser Glu Lys Asp Leu Ile Leu Ala 195 200 205 Leu Gly Val Leu Ala Gln Ser Arg Pro Val Ser Arg His Ser Arg Val 210 215 220 Pro Trp Arg Arg Leu Phe Arg Lys Pro Ala Val Trp Ala Ala Val Val 225 230 235 240 Ser Gln Leu Ser Ala Ala Cys Ser Phe Phe Ile Leu Leu Ser Trp Leu 245 250 255 Pro Thr Phe Phe Glu Glu Thr Phe Pro Asp Ala Lys Gly Trp Ile Phe 260 265 270 Asn Val Val Pro Trp Leu Val Ala Ile Pro Ala Ser Leu Phe Ser Gly 275 280 285 Phe Leu Ser Asp His Leu Ile Asn Gln Gly Tyr Arg Ala Ile Thr Val 290 295 300 Arg Lys Leu Met Gln Gly Met Gly Leu Gly Leu Ser Ser Val Phe Ala 305 310 315 320 Leu Cys Leu Gly His Thr Ser Ser Phe Cys Glu Ser Val Val Phe Ala 325 330 335 Ser Ala Ser Ile Gly Leu Gln Thr Phe Asn His Ser Gly Ile Ser Val 340 345 350 Asn Ile Gln Asp Leu Ala Pro Ser Cys Ala Gly Phe Leu Phe Gly Val 355 360 365 Ala Asn Thr Ala Gly Ala Leu Ala Gly Val Val Gly Val Cys Leu Gly 370 375 380 Gly Tyr Leu Met Glu Thr Thr Gly Ser Trp Thr Cys Leu Phe Asn Leu 385 390 395 400 Val Ala Ile Ile Ser Asn Leu Gly Leu Cys Thr Phe Leu Val Phe Gly 405 410 415 Gln Ala Gln Arg Val Asp Leu Ser Ser Thr His Glu Asp Leu 420 425 430 25 1257 DNA homo sapiens 25 atgttcccca ggccaggggc attgtcctgg acagtcagga ggcatacccc tcgccaggtg 60 gaaccaccct gtgtatgcat gaccctgaca agcaggcgcc aggacagtca ggaggccagg 120 cccgagtgcc aggcatggac ggggacgctg ctgctgggca cgtgccttct gtactgcgcc 180 cgctccagca tgcccatctg caccgtctcc atgagccagg acttcggctg gaacaagaag 240 gaggccggca tcgtgctcag cagcttcttc tggggctact gcctgacaca ggttgtgggc 300 ggccacctcg gggatcggat tgggggtgag aaggtcatcc tgctgtcagc ctctgcctgg 360 ggctccatca cggccgtcac cccactgctc gcccacctga gcagtgccca cctggccttc 420 atgaccttct cacgcatcct catgggcttg ctccaagggg tttacttccc tgccctgacc 480 agcctgctgt cgcagaaggt gcgggagagt gagcgagcct tcacctacag catcgtgggc 540 gccggctccc agtttgggac gctgctgacc ggggcggtgg gctccctgct cctggaatgg 600 tacggctggc agagcatctt ctatttctcc ggcggcctca ccttgctttg ggtgtggtac 660 gtgtacaggt acctgctgag tgaaaaagat ctcatcctgg ccttgggtgt cctggcccaa 720 agccggccgg tgtccaggca cagcagagtc ccctggagac ggctcttccg gaagcctgct 780 gtctgggcag ccgtcgtctc ccagctctct gcagcctgct ccttcttcat cctcctctcc 840 tggctgccca ccttcttcga ggagaccttc cccgacgcca agggctggat cttcaacgtg 900 gttccttggt tggtggcgat tccggccagt ctattcagcg ggtttctctc tgatcatctc 960 atcaatcagg gttacagagc catcacggtg cggaagctca tgcagggcat gggccttggc 1020 ctctccagcg tctttgctct gtgcctgggc cacacctcca gcttctgtga gtctgtggtc 1080 tttgcatcag cctccatcgg cctccagacc ttcaaccaca gtggcatttc tgttaacatc 1140 caggacttgg ccccgtcctg cgccggcttt ctgtttggtg tggccaacac agccggggcc 1200 ttggcaggtg aggggcgggc ctctgtgccc aggagttccc ctgtctgtgg ggtttga 1257 26 418 PRT homo sapiens 26 Met Phe Pro Arg Pro Gly Ala Leu Ser Trp Thr Val Arg Arg His Thr 1 5 10 15 Pro Arg Gln Val Glu Pro Pro Cys Val Cys Met Thr Leu Thr Ser Arg 20 25 30 Arg Gln Asp Ser Gln Glu Ala Arg Pro Glu Cys Gln Ala Trp Thr Gly 35 40 45 Thr Leu Leu Leu Gly Thr Cys Leu Leu Tyr Cys Ala Arg Ser Ser Met 50 55 60 Pro Ile Cys Thr Val Ser Met Ser Gln Asp Phe Gly Trp Asn Lys Lys 65 70 75 80 Glu Ala Gly Ile Val Leu Ser Ser Phe Phe Trp Gly Tyr Cys Leu Thr 85 90 95 Gln Val Val Gly Gly His Leu Gly Asp Arg Ile Gly Gly Glu Lys Val 100 105 110 Ile Leu Leu Ser Ala Ser Ala Trp Gly Ser Ile Thr Ala Val Thr Pro 115 120 125 Leu Leu Ala His Leu Ser Ser Ala His Leu Ala Phe Met Thr Phe Ser 130 135 140 Arg Ile Leu Met Gly Leu Leu Gln Gly Val Tyr Phe Pro Ala Leu Thr 145 150 155 160 Ser Leu Leu Ser Gln Lys Val Arg Glu Ser Glu Arg Ala Phe Thr Tyr 165 170 175 Ser Ile Val Gly Ala Gly Ser Gln Phe Gly Thr Leu Leu Thr Gly Ala 180 185 190 Val Gly Ser Leu Leu Leu Glu Trp Tyr Gly Trp Gln Ser Ile Phe Tyr 195 200 205 Phe Ser Gly Gly Leu Thr Leu Leu Trp Val Trp Tyr Val Tyr Arg Tyr 210 215 220 Leu Leu Ser Glu Lys Asp Leu Ile Leu Ala Leu Gly Val Leu Ala Gln 225 230 235 240 Ser Arg Pro Val Ser Arg His Ser Arg Val Pro Trp Arg Arg Leu Phe 245 250 255 Arg Lys Pro Ala Val Trp Ala Ala Val Val Ser Gln Leu Ser Ala Ala 260 265 270 Cys Ser Phe Phe Ile Leu Leu Ser Trp Leu Pro Thr Phe Phe Glu Glu 275 280 285 Thr Phe Pro Asp Ala Lys Gly Trp Ile Phe Asn Val Val Pro Trp Leu 290 295 300 Val Ala Ile Pro Ala Ser Leu Phe Ser Gly Phe Leu Ser Asp His Leu 305 310 315 320 Ile Asn Gln Gly Tyr Arg Ala Ile Thr Val Arg Lys Leu Met Gln Gly 325 330 335 Met Gly Leu Gly Leu Ser Ser Val Phe Ala Leu Cys Leu Gly His Thr 340 345 350 Ser Ser Phe Cys Glu Ser Val Val Phe Ala Ser Ala Ser Ile Gly Leu 355 360 365 Gln Thr Phe Asn His Ser Gly Ile Ser Val Asn Ile Gln Asp Leu Ala 370 375 380 Pro Ser Cys Ala Gly Phe Leu Phe Gly Val Ala Asn Thr Ala Gly Ala 385 390 395 400 Leu Ala Gly Glu Gly Arg Ala Ser Val Pro Arg Ser Ser Pro Val Cys 405 410 415 Gly Val 27 1068 DNA homo sapiens 27 atgcccatct gcaccgtctc catgagccag gacttcggct ggaacaagaa ggaggccggc 60 atcgtgctca gcagcttctt ctggggctac tgcctgacac aggttgtggg cggccacctc 120 ggggatcgga ttgggggtga gaaggtcatc ctgctgtcag cctctgcctg gggctccatc 180 acggccgtca ccccactgct cgcccacctg agcagtgccc acctggcctt catgaccttc 240 tcacgcatcc tcatgggctt gctccaaggg gtttacttcc ctgccctgac cagcctgctg 300 tcgcagaagg tgcgggagag tgagcgagcc ttcacctaca gcatcgtggg cgccggctcc 360 cagtttggga cgctgctgac cggggcggtg ggctccctgc tcctggaatg gtacggctgg 420 cagagcatct tctatttctc cggcggcctc accttgcttt gggtgtggta cgtgtacagg 480 tacctgctga gtgaaaaaga tctcatcctg gccttgggtg tcctggccca aagccggccg 540 gtgtccaggc acagcagagt cccctggaga cggctcttcc ggaagcctgc tgtctgggca 600 gccgtcgtct cccagctctc tgcagcctgc tccttcttca tcctcctctc ctggctgccc 660 accttcttcg aggagacctt ccccgacgcc aagggctgga tcttcaacgt ggttccttgg 720 ttggtggcga ttccggccag tctattcagc gggtttctct ctgatcatct catcaatcag 780 ggttacagag ccatcacggt gcggaagctc atgcagggca tgggccttgg cctctccagc 840 gtctttgctc tgtgcctggg ccacacctcc agcttctgtg agtctgtggt ctttgcatca 900 gcctccatcg gcctccagac cttcaaccac agtggcattt ctgttaacat ccaggacttg 960 gccccgtcct gcgccggctt tctgtttggt gtggccaaca cagccggggc cttggcaggt 1020 gaggggcggg cctctgtgcc caggagttcc cctgtctgtg gggtttga 1068 28 355 PRT homo sapiens 28 Met Pro Ile Cys Thr Val Ser Met Ser Gln Asp Phe Gly Trp Asn Lys 1 5 10 15 Lys Glu Ala Gly Ile Val Leu Ser Ser Phe Phe Trp Gly Tyr Cys Leu 20 25 30 Thr Gln Val Val Gly Gly His Leu Gly Asp Arg Ile Gly Gly Glu Lys 35 40 45 Val Ile Leu Leu Ser Ala Ser Ala Trp Gly Ser Ile Thr Ala Val Thr 50 55 60 Pro Leu Leu Ala His Leu Ser Ser Ala His Leu Ala Phe Met Thr Phe 65 70 75 80 Ser Arg Ile Leu Met Gly Leu Leu Gln Gly Val Tyr Phe Pro Ala Leu 85 90 95 Thr Ser Leu Leu Ser Gln Lys Val Arg Glu Ser Glu Arg Ala Phe Thr 100 105 110 Tyr Ser Ile Val Gly Ala Gly Ser Gln Phe Gly Thr Leu Leu Thr Gly 115 120 125 Ala Val Gly Ser Leu Leu Leu Glu Trp Tyr Gly Trp Gln Ser Ile Phe 130 135 140 Tyr Phe Ser Gly Gly Leu Thr Leu Leu Trp Val Trp Tyr Val Tyr Arg 145 150 155 160 Tyr Leu Leu Ser Glu Lys Asp Leu Ile Leu Ala Leu Gly Val Leu Ala 165 170 175 Gln Ser Arg Pro Val Ser Arg His Ser Arg Val Pro Trp Arg Arg Leu 180 185 190 Phe Arg Lys Pro Ala Val Trp Ala Ala Val Val Ser Gln Leu Ser Ala 195 200 205 Ala Cys Ser Phe Phe Ile Leu Leu Ser Trp Leu Pro Thr Phe Phe Glu 210 215 220 Glu Thr Phe Pro Asp Ala Lys Gly Trp Ile Phe Asn Val Val Pro Trp 225 230 235 240 Leu Val Ala Ile Pro Ala Ser Leu Phe Ser Gly Phe Leu Ser Asp His 245 250 255 Leu Ile Asn Gln Gly Tyr Arg Ala Ile Thr Val Arg Lys Leu Met Gln 260 265 270 Gly Met Gly Leu Gly Leu Ser Ser Val Phe Ala Leu Cys Leu Gly His 275 280 285 Thr Ser Ser Phe Cys Glu Ser Val Val Phe Ala Ser Ala Ser Ile Gly 290 295 300 Leu Gln Thr Phe Asn His Ser Gly Ile Ser Val Asn Ile Gln Asp Leu 305 310 315 320 Ala Pro Ser Cys Ala Gly Phe Leu Phe Gly Val Ala Asn Thr Ala Gly 325 330 335 Ala Leu Ala Gly Glu Gly Arg Ala Ser Val Pro Arg Ser Ser Pro Val 340 345 350 Cys Gly Val 355 29 933 DNA homo sapiens 29 atgttcccca ggccaggggc attgtcctgg acagtcagga ggcatacccc tcgccaggtg 60 gaaccaccct gtgtatgcat gaccctgaca agcaggcgcc aggacagtca ggaggccagg 120 cccgagtgcc aggcatggac ggggacgctg ctgctgggca cgtgccttct gtactgcgcc 180 cgctccagca tgcccatctg caccgtctcc atgagccagg acttcggctg gaacaagaag 240 gaggccggca tcgtgctcag cagcttcttc tggggctact gcctgacaca ggttgtgggc 300 ggccacctcg gggatcggat tgggggtgag aaggtcatcc tgctgtcagc ctctgcctgg 360 ggctccatca cggccgtcac cccactgctc gcccacctga gcagtgccca cctggccttc 420 atgaccttct cacgcatcct catgggcttg ctccaagggg tttacttccc tgccctgacc 480 agcctgctgt cgcagaaggt gcgggagagt gagcgagcct tcacctacag catcgtgggc 540 gccggctccc agtttgggac gctgctgacc ggggcggtgg gctccctgct cctggaatgg 600 tacggctggc agagcatctt ctatttctcc ggcggcctca ccttgctttg ggtgtggtac 660 gtgtacagat ctcatcctgg ccttgggtgt cctggcccaa agccggccgg tgtccaggca 720 cagcagagtc ccctggagac ggctcttccg gaagcctgct gtctgggcag ccgtcgtctc 780 ccagctctct gcagcctgct ccttcttcat cctcctctcc tggctgccca ccttcttcga 840 ggagaccttc cccgacgcca agggctggat cttcaacgtg gttccttggt tggtggcgat 900 tccggccagt ctattcagcg ggtttctctc tga 933 30 310 PRT homo sapiens 30 Met Phe Pro Arg Pro Gly Ala Leu Ser Trp Thr Val Arg Arg His Thr 1 5 10 15 Pro Arg Gln Val Glu Pro Pro Cys Val Cys Met Thr Leu Thr Ser Arg 20 25 30 Arg Gln Asp Ser Gln Glu Ala Arg Pro Glu Cys Gln Ala Trp Thr Gly 35 40 45 Thr Leu Leu Leu Gly Thr Cys Leu Leu Tyr Cys Ala Arg Ser Ser Met 50 55 60 Pro Ile Cys Thr Val Ser Met Ser Gln Asp Phe Gly Trp Asn Lys Lys 65 70 75 80 Glu Ala Gly Ile Val Leu Ser Ser Phe Phe Trp Gly Tyr Cys Leu Thr 85 90 95 Gln Val Val Gly Gly His Leu Gly Asp Arg Ile Gly Gly Glu Lys Val 100 105 110 Ile Leu Leu Ser Ala Ser Ala Trp Gly Ser Ile Thr Ala Val Thr Pro 115 120 125 Leu Leu Ala His Leu Ser Ser Ala His Leu Ala Phe Met Thr Phe Ser 130 135 140 Arg Ile Leu Met Gly Leu Leu Gln Gly Val Tyr Phe Pro Ala Leu Thr 145 150 155 160 Ser Leu Leu Ser Gln Lys Val Arg Glu Ser Glu Arg Ala Phe Thr Tyr 165 170 175 Ser Ile Val Gly Ala Gly Ser Gln Phe Gly Thr Leu Leu Thr Gly Ala 180 185 190 Val Gly Ser Leu Leu Leu Glu Trp Tyr Gly Trp Gln Ser Ile Phe Tyr 195 200 205 Phe Ser Gly Gly Leu Thr Leu Leu Trp Val Trp Tyr Val Tyr Arg Ser 210 215 220 His Pro Gly Leu Gly Cys Pro Gly Pro Lys Pro Ala Gly Val Gln Ala 225 230 235 240 Gln Gln Ser Pro Leu Glu Thr Ala Leu Pro Glu Ala Cys Cys Leu Gly 245 250 255 Ser Arg Arg Leu Pro Ala Leu Cys Ser Leu Leu Leu Leu His Pro Pro 260 265 270 Leu Leu Ala Ala His Leu Leu Arg Gly Asp Leu Pro Arg Arg Gln Gly 275 280 285 Leu Asp Leu Gln Arg Gly Ser Leu Val Gly Gly Asp Ser Gly Gln Ser 290 295 300 Ile Gln Arg Val Ser Leu 305 310 31 744 DNA homo sapiens 31 atgcccatct gcaccgtctc catgagccag gacttcggct ggaacaagaa ggaggccggc 60 atcgtgctca gcagcttctt ctggggctac tgcctgacac aggttgtggg cggccacctc 120 ggggatcgga ttgggggtga gaaggtcatc ctgctgtcag cctctgcctg gggctccatc 180 acggccgtca ccccactgct cgcccacctg agcagtgccc acctggcctt catgaccttc 240 tcacgcatcc tcatgggctt gctccaaggg gtttacttcc ctgccctgac cagcctgctg 300 tcgcagaagg tgcgggagag tgagcgagcc ttcacctaca gcatcgtggg cgccggctcc 360 cagtttggga cgctgctgac cggggcggtg ggctccctgc tcctggaatg gtacggctgg 420 cagagcatct tctatttctc cggcggcctc accttgcttt gggtgtggta cgtgtacaga 480 tctcatcctg gccttgggtg tcctggccca aagccggccg gtgtccaggc acagcagagt 540 cccctggaga cggctcttcc ggaagcctgc tgtctgggca gccgtcgtct cccagctctc 600 tgcagcctgc tccttcttca tcctcctctc ctggctgccc accttcttcg aggagacctt 660 ccccgacgcc aagggctgga tcttcaacgt ggttccttgg ttggtggcga ttccggccag 720 tctattcagc gggtttctct ctga 744 32 247 PRT homo sapiens 32 Met Pro Ile Cys Thr Val Ser Met Ser Gln Asp Phe Gly Trp Asn Lys 1 5 10 15 Lys Glu Ala Gly Ile Val Leu Ser Ser Phe Phe Trp Gly Tyr Cys Leu 20 25 30 Thr Gln Val Val Gly Gly His Leu Gly Asp Arg Ile Gly Gly Glu Lys 35 40 45 Val Ile Leu Leu Ser Ala Ser Ala Trp Gly Ser Ile Thr Ala Val Thr 50 55 60 Pro Leu Leu Ala His Leu Ser Ser Ala His Leu Ala Phe Met Thr Phe 65 70 75 80 Ser Arg Ile Leu Met Gly Leu Leu Gln Gly Val Tyr Phe Pro Ala Leu 85 90 95 Thr Ser Leu Leu Ser Gln Lys Val Arg Glu Ser Glu Arg Ala Phe Thr 100 105 110 Tyr Ser Ile Val Gly Ala Gly Ser Gln Phe Gly Thr Leu Leu Thr Gly 115 120 125 Ala Val Gly Ser Leu Leu Leu Glu Trp Tyr Gly Trp Gln Ser Ile Phe 130 135 140 Tyr Phe Ser Gly Gly Leu Thr Leu Leu Trp Val Trp Tyr Val Tyr Arg 145 150 155 160 Ser His Pro Gly Leu Gly Cys Pro Gly Pro Lys Pro Ala Gly Val Gln 165 170 175 Ala Gln Gln Ser Pro Leu Glu Thr Ala Leu Pro Glu Ala Cys Cys Leu 180 185 190 Gly Ser Arg Arg Leu Pro Ala Leu Cys Ser Leu Leu Leu Leu His Pro 195 200 205 Pro Leu Leu Ala Ala His Leu Leu Arg Gly Asp Leu Pro Arg Arg Gln 210 215 220 Gly Leu Asp Leu Gln Arg Gly Ser Leu Val Gly Gly Asp Ser Gly Gln 225 230 235 240 Ser Ile Gln Arg Val Ser Leu 245 33 1371 DNA homo sapiens 33 atgttcccca ggccaggggc attgtcctgg acagtcagga ggcatacccc tcgccaggtg 60 gaaccaccct gtgtatgcat gaccctgaca agcaggcgcc aggacagtca ggaggccagg 120 cccgagtgcc aggcatggac ggggacgctg ctgctgggca cgtgccttct gtactgcgcc 180 cgctccagca tgcccatctg caccgtctcc atgagccagg acttcggctg gaacaagaag 240 gaggccggca tcgtgctcag cagcttcttc tggggctact gcctgacaca ggttgtgggc 300 ggccacctcg gggatcggat tgggggtgag aaggtcatcc tgctgtcagc ctctgcctgg 360 ggctccatca cggccgtcac cccactgctc gcccacctga gcagtgccca cctggccttc 420 atgaccttct cacgcatcct catgggcttg ctccaagggg tttacttccc tgccctgacc 480 agcctgctgt cgcagaaggt gcgggagagt gagcgagcct tcacctacag catcgtgggc 540 gccggctccc agtttgggac gctgctgacc ggggcggtgg gctccctgct cctggaatgg 600 tacggctggc agagcatctt ctatttctcc ggcggcctca ccttgctttg ggtgtggtac 660 gtgtacaggt acctgctgag tgaaaaagat ctcatcctgg ccttgggtgt cctggcccaa 720 agccggccgg tgtccaggca cagcagagtc ccctggagac ggctcttccg gaagcctgct 780 gtctgggcag ccgtcgtctc ccagctctct gcagcctgct ccttcttcat cctcctctcc 840 tggctgccca ccttcttcga ggagaccttc cccgacgcca agggctggat cttcaacgtg 900 gttccttggt tggtggcgat tccggccagt ctattcagcg ggtttctctc tgatcatctc 960 atcaatcagg gttacagagc catcacggtg cggaagctca tgcagggcat gggccttggc 1020 ctctccagcg tctttgctct gtgcctgggc cacacctcca gcttctgtga gtctgtggtc 1080 tttgcatcag cctccatcgg cctccagacc ttcaaccaca gtggcatttc tgttaacatc 1140 caggacttgg ccccgtcctg cgccggcttt ctgtttggtg tggccaacac agccggggcc 1200 ttggcaggtg tcgtgggtgt gtgtctaggc ggctacttga tggagaccac gggctcctgg 1260 acttgcctgt tcaaccttgt ggccatcatc agcaacctgg ggctgtgcac cttcctggtg 1320 tttggacagg ctcagagggt ggacctgagc tctacccatg aggacctcta g 1371 34 456 PRT homo sapiens 34 Met Phe Pro Arg Pro Gly Ala Leu Ser Trp Thr Val Arg Arg His Thr 1 5 10 15 Pro Arg Gln Val Glu Pro Pro Cys Val Cys Met Thr Leu Thr Ser Arg 20 25 30 Arg Gln Asp Ser Gln Glu Ala Arg Pro Glu Cys Gln Ala Trp Thr Gly 35 40 45 Thr Leu Leu Leu Gly Thr Cys Leu Leu Tyr Cys Ala Arg Ser Ser Met 50 55 60 Pro Ile Cys Thr Val Ser Met Ser Gln Asp Phe Gly Trp Asn Lys Lys 65 70 75 80 Glu Ala Gly Ile Val Leu Ser Ser Phe Phe Trp Gly Tyr Cys Leu Thr 85 90 95 Gln Val Val Gly Gly His Leu Gly Asp Arg Ile Gly Gly Glu Lys Val 100 105 110 Ile Leu Leu Ser Ala Ser Ala Trp Gly Ser Ile Thr Ala Val Thr Pro 115 120 125 Leu Leu Ala His Leu Ser Ser Ala His Leu Ala Phe Met Thr Phe Ser 130 135 140 Arg Ile Leu Met Gly Leu Leu Gln Gly Val Tyr Phe Pro Ala Leu Thr 145 150 155 160 Ser Leu Leu Ser Gln Lys Val Arg Glu Ser Glu Arg Ala Phe Thr Tyr 165 170 175 Ser Ile Val Gly Ala Gly Ser Gln Phe Gly Thr Leu Leu Thr Gly Ala 180 185 190 Val Gly Ser Leu Leu Leu Glu Trp Tyr Gly Trp Gln Ser Ile Phe Tyr 195 200 205 Phe Ser Gly Gly Leu Thr Leu Leu Trp Val Trp Tyr Val Tyr Arg Tyr 210 215 220 Leu Leu Ser Glu Lys Asp Leu Ile Leu Ala Leu Gly Val Leu Ala Gln 225 230 235 240 Ser Arg Pro Val Ser Arg His Ser Arg Val Pro Trp Arg Arg Leu Phe 245 250 255 Arg Lys Pro Ala Val Trp Ala Ala Val Val Ser Gln Leu Ser Ala Ala 260 265 270 Cys Ser Phe Phe Ile Leu Leu Ser Trp Leu Pro Thr Phe Phe Glu Glu 275 280 285 Thr Phe Pro Asp Ala Lys Gly Trp Ile Phe Asn Val Val Pro Trp Leu 290 295 300 Val Ala Ile Pro Ala Ser Leu Phe Ser Gly Phe Leu Ser Asp His Leu 305 310 315 320 Ile Asn Gln Gly Tyr Arg Ala Ile Thr Val Arg Lys Leu Met Gln Gly 325 330 335 Met Gly Leu Gly Leu Ser Ser Val Phe Ala Leu Cys Leu Gly His Thr 340 345 350 Ser Ser Phe Cys Glu Ser Val Val Phe Ala Ser Ala Ser Ile Gly Leu 355 360 365 Gln Thr Phe Asn His Ser Gly Ile Ser Val Asn Ile Gln Asp Leu Ala 370 375 380 Pro Ser Cys Ala Gly Phe Leu Phe Gly Val Ala Asn Thr Ala Gly Ala 385 390 395 400 Leu Ala Gly Val Val Gly Val Cys Leu Gly Gly Tyr Leu Met Glu Thr 405 410 415 Thr Gly Ser Trp Thr Cys Leu Phe Asn Leu Val Ala Ile Ile Ser Asn 420 425 430 Leu Gly Leu Cys Thr Phe Leu Val Phe Gly Gln Ala Gln Arg Val Asp 435 440 445 Leu Ser Ser Thr His Glu Asp Leu 450 455 35 1182 DNA homo sapiens 35 atgcccatct gcaccgtctc catgagccag gacttcggct ggaacaagaa ggaggccggc 60 atcgtgctca gcagcttctt ctggggctac tgcctgacac aggttgtggg cggccacctc 120 ggggatcgga ttgggggtga gaaggtcatc ctgctgtcag cctctgcctg gggctccatc 180 acggccgtca ccccactgct cgcccacctg agcagtgccc acctggcctt catgaccttc 240 tcacgcatcc tcatgggctt gctccaaggg gtttacttcc ctgccctgac cagcctgctg 300 tcgcagaagg tgcgggagag tgagcgagcc ttcacctaca gcatcgtggg cgccggctcc 360 cagtttggga cgctgctgac cggggcggtg ggctccctgc tcctggaatg gtacggctgg 420 cagagcatct tctatttctc cggcggcctc accttgcttt gggtgtggta cgtgtacagg 480 tacctgctga gtgaaaaaga tctcatcctg gccttgggtg tcctggccca aagccggccg 540 gtgtccaggc acagcagagt cccctggaga cggctcttcc ggaagcctgc tgtctgggca 600 gccgtcgtct cccagctctc tgcagcctgc tccttcttca tcctcctctc ctggctgccc 660 accttcttcg aggagacctt ccccgacgcc aagggctgga tcttcaacgt ggttccttgg 720 ttggtggcga ttccggccag tctattcagc gggtttctct ctgatcatct catcaatcag 780 ggttacagag ccatcacggt gcggaagctc atgcagggca tgggccttgg cctctccagc 840 gtctttgctc tgtgcctggg ccacacctcc agcttctgtg agtctgtggt ctttgcatca 900 gcctccatcg gcctccagac cttcaaccac agtggcattt ctgttaacat ccaggacttg 960 gccccgtcct gcgccggctt tctgtttggt gtggccaaca cagccggggc cttggcaggt 1020 gtcgtgggtg tgtgtctagg cggctacttg atggagacca cgggctcctg gacttgcctg 1080 ttcaaccttg tggccatcat cagcaacctg gggctgtgca ccttcctggt gtttggacag 1140 gctcagaggg tggacctgag ctctacccat gaggacctct ag 1182 36 393 PRT homo sapiens 36 Met Pro Ile Cys Thr Val Ser Met Ser Gln Asp Phe Gly Trp Asn Lys 1 5 10 15 Lys Glu Ala Gly Ile Val Leu Ser Ser Phe Phe Trp Gly Tyr Cys Leu 20 25 30 Thr Gln Val Val Gly Gly His Leu Gly Asp Arg Ile Gly Gly Glu Lys 35 40 45 Val Ile Leu Leu Ser Ala Ser Ala Trp Gly Ser Ile Thr Ala Val Thr 50 55 60 Pro Leu Leu Ala His Leu Ser Ser Ala His Leu Ala Phe Met Thr Phe 65 70 75 80 Ser Arg Ile Leu Met Gly Leu Leu Gln Gly Val Tyr Phe Pro Ala Leu 85 90 95 Thr Ser Leu Leu Ser Gln Lys Val Arg Glu Ser Glu Arg Ala Phe Thr 100 105 110 Tyr Ser Ile Val Gly Ala Gly Ser Gln Phe Gly Thr Leu Leu Thr Gly 115 120 125 Ala Val Gly Ser Leu Leu Leu Glu Trp Tyr Gly Trp Gln Ser Ile Phe 130 135 140 Tyr Phe Ser Gly Gly Leu Thr Leu Leu Trp Val Trp Tyr Val Tyr Arg 145 150 155 160 Tyr Leu Leu Ser Glu Lys Asp Leu Ile Leu Ala Leu Gly Val Leu Ala 165 170 175 Gln Ser Arg Pro Val Ser Arg His Ser Arg Val Pro Trp Arg Arg Leu 180 185 190 Phe Arg Lys Pro Ala Val Trp Ala Ala Val Val Ser Gln Leu Ser Ala 195 200 205 Ala Cys Ser Phe Phe Ile Leu Leu Ser Trp Leu Pro Thr Phe Phe Glu 210 215 220 Glu Thr Phe Pro Asp Ala Lys Gly Trp Ile Phe Asn Val Val Pro Trp 225 230 235 240 Leu Val Ala Ile Pro Ala Ser Leu Phe Ser Gly Phe Leu Ser Asp His 245 250 255 Leu Ile Asn Gln Gly Tyr Arg Ala Ile Thr Val Arg Lys Leu Met Gln 260 265 270 Gly Met Gly Leu Gly Leu Ser Ser Val Phe Ala Leu Cys Leu Gly His 275 280 285 Thr Ser Ser Phe Cys Glu Ser Val Val Phe Ala Ser Ala Ser Ile Gly 290 295 300 Leu Gln Thr Phe Asn His Ser Gly Ile Ser Val Asn Ile Gln Asp Leu 305 310 315 320 Ala Pro Ser Cys Ala Gly Phe Leu Phe Gly Val Ala Asn Thr Ala Gly 325 330 335 Ala Leu Ala Gly Val Val Gly Val Cys Leu Gly Gly Tyr Leu Met Glu 340 345 350 Thr Thr Gly Ser Trp Thr Cys Leu Phe Asn Leu Val Ala Ile Ile Ser 355 360 365 Asn Leu Gly Leu Cys Thr Phe Leu Val Phe Gly Gln Ala Gln Arg Val 370 375 380 Asp Leu Ser Ser Thr His Glu Asp Leu 385 390 37 1428 DNA homo sapiens 37 atggccgttg tctcagagga cgactttcag cacagttcaa actccaccta cggaaccaca 60 agcagcagtc tccgagctga ccaggaggca ctgcttgaga agctgctgga ccgcccgccc 120 cctggcctgc agaggcccga ggaccgcttc tgtggcacat acatcatctt cttcagcctg 180 ggcattggca gtctactgcc atggaacttc tttatcactg ccaaggagta ctggatgttc 240 aaactccgca actcctccag cccagccacc ggggaggacc ctgagggctc agacatcctg 300 aactactttg agagctacct tgccgttgcc tccaccgtgc cctccatgct gtgcctggtg 360 gccaacttcc tgcttgtcaa cagggttgca gtccacatcc gtgtcctggc ctcactgacg 420 gtcatcctgg ccatcttcat ggtgataact gcactggtga aggtggacac tttctcctgg 480 acccgtggct tttttgcggt caccattgtc tgcatggtga tcctcagcgg tgcctccact 540 gtcttcagca gcagcatcta cggcatgacc ggctcctttc ctatgaggaa ctcccaggca 600 ctgatatcag gaggagccat gggcgggacg gtcagcgccg tggcctcatt ggtggacttg 660 gctgcatcca gtgatgtgag gaacagcgcc ctggccttct tcctgacggc caccatcttc 720 ctcgtgctct gcatgggact ctacctgctg ctgtccaggc tggagtatgc caggtactac 780 atgaggcctg ttcttgcggc ccatgtgttt tctggtgaag aggagcttcc ccaggactcc 840 ctcagtgccc cttcggtggc ctccagattc attgattccc acacaccccc tctccgcccc 900 atcctgaaga agacggccag cctgggcttc tgtgtcacct acgtcttctt catcaccagc 960 ctcatctacc ccgccgtctg caccaacatc gagtccctca acaagggctc gggctcactg 1020 tggaccacca agtttttcat ccccctcact accttcctcc tgtacaactt tgctgaccta 1080 tgtggccggc agctcaccgc ctggatccag gtgccagggc ccaatagcaa ggcgctccca 1140 gggttcgtgc tcctccggac ctgcctcatc cccctcttcg tgctctgtaa ctaccagccc 1200 cgcgtccacc tgaagactgt ggtcttccag tccgatgtgt accccgcact cctcagctcc 1260 ctgctggggc tcagcaacgg ctacctcagc accctggccc tcctctacgg gcctaagatt 1320 gtgcccaggg agctggctga ggccacggga gtggtgatgt ccttttatgt gtgcttgggc 1380 ttaacactgg gctcagcctg ctctaccctc ctggtgcacc tcatctag 1428 38 475 PRT homo sapiens 38 Met Ala Val Val Ser Glu Asp Asp Phe Gln His Ser Ser Asn Ser Thr 1 5 10 15 Tyr Gly Thr Thr Ser Ser Ser Leu Arg Ala Asp Gln Glu Ala Leu Leu 20 25 30 Glu Lys Leu Leu Asp Arg Pro Pro Pro Gly Leu Gln Arg Pro Glu Asp 35 40 45 Arg Phe Cys Gly Thr Tyr Ile Ile Phe Phe Ser Leu Gly Ile Gly Ser 50 55 60 Leu Leu Pro Trp Asn Phe Phe Ile Thr Ala Lys Glu Tyr Trp Met Phe 65 70 75 80 Lys Leu Arg Asn Ser Ser Ser Pro Ala Thr Gly Glu Asp Pro Glu Gly 85 90 95 Ser Asp Ile Leu Asn Tyr Phe Glu Ser Tyr Leu Ala Val Ala Ser Thr 100 105 110 Val Pro Ser Met Leu Cys Leu Val Ala Asn Phe Leu Leu Val Asn Arg 115 120 125 Val Ala Val His Ile Arg Val Leu Ala Ser Leu Thr Val Ile Leu Ala 130 135 140 Ile Phe Met Val Ile Thr Ala Leu Val Lys Val Asp Thr Phe Ser Trp 145 150 155 160 Thr Arg Gly Phe Phe Ala Val Thr Ile Val Cys Met Val Ile Leu Ser 165 170 175 Gly Ala Ser Thr Val Phe Ser Ser Ser Ile Tyr Gly Met Thr Gly Ser 180 185 190 Phe Pro Met Arg Asn Ser Gln Ala Leu Ile Ser Gly Gly Ala Met Gly 195 200 205 Gly Thr Val Ser Ala Val Ala Ser Leu Val Asp Leu Ala Ala Ser Ser 210 215 220 Asp Val Arg Asn Ser Ala Leu Ala Phe Phe Leu Thr Ala Thr Ile Phe 225 230 235 240 Leu Val Leu Cys Met Gly Leu Tyr Leu Leu Leu Ser Arg Leu Glu Tyr 245 250 255 Ala Arg Tyr Tyr Met Arg Pro Val Leu Ala Ala His Val Phe Ser Gly 260 265 270 Glu Glu Glu Leu Pro Gln Asp Ser Leu Ser Ala Pro Ser Val Ala Ser 275 280 285 Arg Phe Ile Asp Ser His Thr Pro Pro Leu Arg Pro Ile Leu Lys Lys 290 295 300 Thr Ala Ser Leu Gly Phe Cys Val Thr Tyr Val Phe Phe Ile Thr Ser 305 310 315 320 Leu Ile Tyr Pro Ala Val Cys Thr Asn Ile Glu Ser Leu Asn Lys Gly 325 330 335 Ser Gly Ser Leu Trp Thr Thr Lys Phe Phe Ile Pro Leu Thr Thr Phe 340 345 350 Leu Leu Tyr Asn Phe Ala Asp Leu Cys Gly Arg Gln Leu Thr Ala Trp 355 360 365 Ile Gln Val Pro Gly Pro Asn Ser Lys Ala Leu Pro Gly Phe Val Leu 370 375 380 Leu Arg Thr Cys Leu Ile Pro Leu Phe Val Leu Cys Asn Tyr Gln Pro 385 390 395 400 Arg Val His Leu Lys Thr Val Val Phe Gln Ser Asp Val Tyr Pro Ala 405 410 415 Leu Leu Ser Ser Leu Leu Gly Leu Ser Asn Gly Tyr Leu Ser Thr Leu 420 425 430 Ala Leu Leu Tyr Gly Pro Lys Ile Val Pro Arg Glu Leu Ala Glu Ala 435 440 445 Thr Gly Val Val Met Ser Phe Tyr Val Cys Leu Gly Leu Thr Leu Gly 450 455 460 Ser Ala Cys Ser Thr Leu Leu Val His Leu Ile 465 470 475 39 2316 DNA Homo sapiens 39 ctgggactga cacgtggact tgggcggtgc tgcccgggtg ggtcagcctg ggctgggagg 60 cagccccggg acacagctgt gcccacgccg tctgagcacc ccaagcccga tgcagccacc 120 cccagacgag gcccgcaggg acatggccgg ggacacccag tggtccaggt ggaaccaccc 180 tgtgtatgca tgaccctgac aagcaggcgc caggacagtc aggaggccag gcccgagtgc 240 caggcatgga cggggacgct gctgctgggc acgtgccttc tgtactgcgc ccgctccagc 300 atgcccatct gcaccgtctc catgagccag gacttcggct ggaacaagaa ggaggccggc 360 atcgtgctca gcagcttctt ctggggctac tgcctgacac aggttgtggg cggccacctc 420 ggggatcgga ttgggggtga gaaggtcatc ctgctgtcag cctctgcctg gggctccatc 480 acggccgtca ccccactgct cgcccacctg agcagtgccc acctggcctt catgaccttc 540 tcacgcatcc tcatgggctt gctccaaggg gtttacttcc ctgccctgac cagcctgctg 600 tcgcagaagg tgcgggagag tgagcgagcc ttcacctaca gcatcgtggg cgccggctcc 660 cagtttggga cgctgctgac cggggcggtg ggctccctgc tcctggaatg gtacggctgg 720 cagagcatct tctatttctc cggcggcctc accttgcttt gggtgtggta cgtgtacagg 780 tacctgctga gtgaaaaaga tctcatcctg gccttgggtg tcctggccca aagccggccg 840 gtgtccaggc acagcagagt cccctggaga cggctcttcc ggaagcctgc tgtctgggca 900 gccgtcgtct cccagctctc tgcagcctgc tccttcttca tcctcctctc ctggctgccc 960 accttcttcg aggagacctt ccccgacgcc aagggctgga tcttcaacgt ggttccttgg 1020 ttggtggcga ttccggccag tctattcagc gggtttctct ctgatcatct catcaatcag 1080 ggttacagag ccatcacggt gcggaagctc atgcagggca tgggccttgg cctctccagc 1140 gtctttgctc tgtgcctggg ccacacctcc agcttctgtg agtctgtggt ctttgcatca 1200 gcctccatcg gcctccagac cttcaaccac agtggcattt ctgttaacat ccaggacttg 1260 gccccgtcct gcgccggctt tctgtttggt gtggccaaca cagccggggc cttggcaggt 1320 gaggggcggg cctctgtgcc caggagttcc cctgtctgtg gggtttgagg ccaccgaggt 1380 gctgcagggt ggggttgtgc ctcccttcag agggggtccg ggtgtcagag gagggcacag 1440 accccagagc aggcccagga gaggaggatg gggctgcctt ccaggttcca ctggactttg 1500 ctgacggcag gtggctcatg agtcgccatc tgccctgact cacagatatg ttcccatcct 1560 ggtagcccag ggtccccggg ataccgcctg gccccgctga gtgccatgga tgatgggggt 1620 ccttcttcag ctcagcctcg cctgggccgg cctgtggctc ccattttcct ttcagcggga 1680 caaaggggac ttgttaccag gccattttct ggatggcctg tgagatctct gcccctccaa 1740 gaccctccaa gtctgagcct gacccacagc tgggacactt gaattcaagc ccttgggaac 1800 catgggggct tctatcaggc gctagatcgt gggtgtgtgt ctaggcggct acttgatgga 1860 gaccacgggc tcctggactt gcctgttcaa ccttgtggcc atcatcagca acctggggct 1920 gtgcaccttc ctggtgtttg gacaggctca gagggtggac ctgagctcta cccatgagga 1980 cctctagctc ccaaccccac agcctctcca aggacccagg cgccagcagc cccgggacac 2040 aggggactca gtgtgtggga cttggtcact ccatgtcaga cacacgagca gagaggaaca 2100 caaaccactg tggagcctga agctccttaa gaagagtcca caacagctgg tgggagggtg 2160 gggtgggcct gggtccagac caggctcgct gctctctggg cctcagtttc cccaccttgc 2220 cagcgggctt cggccctgtc cttctcacag gctggtgtgg cccgtcaagg gtgggtgggg 2280 ttattggtag taggcgcagc ctcatttcca ccacga 2316 40 2316 DNA homo sapiens 40 ctgggactga cacgtggact tgggcggtgc tgcccgggtg ggtcagcctg ggctgggagg 60 cagccccggg acacagctgt gcccacgccg tctgagcacc ccaagcccga tgcagccacc 120 cccagacgag gcccgcaggg acatggccgg ggacacccag tggtccaggt ggaaccaccc 180 tgtgtatgca tgaccctgac aagcaggcgc caggacagtc aggaggccag gcccgagtgc 240 caggcatgga cggggacgct gctgctgggc acgtgccttc tgtactgcgc ccgctccagc 300 atgcccatct gcaccgtctc catgagccag gacttcggct ggaacaagaa ggaggccggc 360 atcgtgctca gcagcttctt ctggggctac tgcctgacac aggttgtggg cggccacctc 420 ggggatcgga ttgggggtga gaaggtcatc ctgctgtcag cctctgcctg gggctccatc 480 acggccgtca ccccactgct cgcccacctg agcagtgccc acctggcctt catgaccttc 540 tcacgcatcc tcatgggctt gctccaaggg gtttacttcc ctgccctgac cagcctgctg 600 tcgcagaagg tgcgggagag tgagcgagcc ttcacctaca gcatcgtggg cgccggctcc 660 cagtttggga cgctgctgac cggggcggtg ggctccctgc tcctggaatg gtacggctgg 720 cagagcatct tctatttctc cggcggcctc accttgcttt gggtgtggta cgtgtacagg 780 tacctgctga gtgaaaaaga tctcatcctg gccttgggtg tcctggccca aagccggccg 840 gtgtccaggc acagcagagt cccctggaga cggctcttcc ggaagcctgc tgtctgggca 900 gccgtcgtct cccagctctc tgcagcctgc tccttcttca tcctcctctc ctggctgccc 960 accttcttcg aggagacctt ccccgacgcc aagggctgga tcttcaacgt ggttccttgg 020 ttggtggcga ttccggccag tctattcagc gggtttctct ctgatcatct catcaatcag 080 ggttacagag ccatcacggt gcggaagctc atgcagggca tgggccttgg cctctccagc 140 gtctttgctc tgtgcctggg ccacacctcc agcttctgtg agtctgtggt ctttgcatca 200 gcctccatcg gcctccagac cttcaaccac agtggcattt ctgttaacat ccaggacttg 260 gccccgtcct gcgccggctt tctgtttggt gtggccaaca cagccggggc cttggcaggt 320 gaggggcggg cctctgtgcc caggagttcc cctgtctgtg gggtttgagg ccaccgaggt 380 gctgcagggt ggggttgtgc ctcccttcag agggggtccg ggtgtcagag gagggcacag 440 accccagagc aggcccagga gaggaggatg gggctgcctt ccaggttcca ctggactttg 500 ctgacggcag gtggctcatg agtcgccatc tgccctgact cacagatatg ttcccatcct 560 ggtagcccag ggtccccggg ataccgcctg gccccgctga gtgccatgga tgatgggggt 620 ccttcttcag ctcagcctcg cctgggccgg cctgtggctc ccattttcct ttcagcggga 680 caaaggggac ttgttaccag gccattttct ggatggcctg tgagatctct gcccctccaa 740 gaccctccaa gtctgagcct gacccacagc tgggacactt gaattcaagc ccttgggaac 800 catgggggct tctatcaggc gctagatcgt gggtgtgtgt ctaggcggct acttgatgga 860 gaccacgggc tcctggactt gcctgttcaa ccttgtggcc atcatcagca acctggggct 920 gtgcaccttc ctggtgtttg gacaggctca gagggtggac ctgagctcta cccatgagga 980 cctctagctc ccaaccccac agcctctcca aggacccagg cgccagcagc cccgggacac 040 aggggactca gtgtgtggga cttggtcact ccatgtcaga cacacgagca gagaggaaca 100 caaaccactg tggagcctga agctccttaa gaagagtcca caacagctgg tgggagggtg 160 gggtgggcct gggtccagac caggctcgct gctctctggg cctcagtttc cccaccttgc 220 cagcgggctt cggccctgtc cttctcacag gctggtgtgg cccgtcaagg gtgggtgggg 280 ttattggtag taggcgcagc ctcatttcca ccacga 316 

What is claimed is:
 1. An isolated nucleic acid molecule comprising at least 24 contiguous bases of nucleotide sequence first disclosed in SEQ ID NO:
 1. 2. An isolated nucleic acid molecule comprising a nucleotide sequence that: (a) encodes the amino acid sequence shown in SEQ ID NO: 2; and (b) hybridizes under stringent conditions to the nucleotide sequence of SEQ ID NO:l or the complement thereof.
 3. An isolated nucleic acid molecule comprising a nucleotide sequence that encodes the amino acid sequence shown in SEQ ID NO:
 2. 4. An isolated nucleic acid molecule comprising a nucleotide sequence that: (a) encodes the amino acid sequence shown in SEQ ID NO: 12; and (b) hybridizes under stringent conditions to the nucleotide sequence of SEQ ID NO: 11 or the complement thereof.
 5. An isolated nucleic acid molecule comprising a nucleotide sequence that encodes the amino acid sequence shown in SEQ ID NO:
 37. 6. An isolated oligopeptide comprising at least about 12 amino acids in a sequence first disclosed in SEQ ID NO:
 38. 7. An isolated nucleic acid molecule comprising at least 24 contiguous bases of nucleotide sequence first disclosed in the NHP sequence described in SEQ ID NO:
 13. 8. An isolated nucleic acid molecule comprising a nucleotide sequence that: a) encodes the amino acid sequence shown in SEQ ID NO: 14; and b) hybridizes under stringent conditions to the nucleotide sequence of SEQ ID NO: 13 or the complement thereof.
 9. An isolated nucleic acid molecule that encodes the amino acid sequence described in SEQ ID NO:
 14. 10. An isolated nucleic acid molecule comprising a nucleotide sequence that: a) encodes the amino acid sequence shown in SEQ ID NO: 24; and b) hybridizes under stringent conditions to the nucleotide sequence of SEQ ID NO: 23 or the complement thereof.
 11. An isolated nucleic acid molecule comprising at least 24 contiguous bases of nucleotide sequence first disclosed in SEQ ID NO:
 25. 12. An isolated nucleic acid molecule comprising a nucleotide sequence that encodes the amino acid sequence shown in SEQ ID NO:
 26. 